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Abstract
This Thesis details research undertaken on the continuing project investigating 
the novel catalytic mechanism of the adenovirus serotype 2 L3 23 kDa 
proteinase. The proteinase is a virally encoded endopeptidase which is essential 
for the successful replication, maturation and spread of infectious virus 
particles. Three tetrapeptide esters were synthesised and tested as potential 
inhibitors. These tetrapeptides were based on the N-terminal minimum 
substrate specificity requirement established by Kemp et al. and are of the 
form;
M(L)XGXiG or M(L)XGGiX.
From these motifs it is clear that there is a very strict requirement at P2 for 
glycine. It is proposed that this requirement is, at least in part, steric and the 
three tetrapeptides synthesised and tested vary the residue at P2 in order to 
establish if this is the case. The three tetrapeptides are;
Cbz-(25)-Leu-(2S)-Ala-Gly-Gly-OPri (9),
Cbz-(25)-Leu-(25)-Ala-(25)-Ala-Gly-OPri(10),
Cbz-(2S)-Leu-(25)-Ala-(2R)-Ala-Gly-OPri(ll).
Leucine was chosen over methionine for simplification of synthesis and the 
isopropyl ester was chosen partly for ease of synthesis and partly to complete 
a series of "wild-type" tetrapeptide esters which are turned over as substrates. 
We show that (9) does not inhibit the proteinase, that (10) inhibits by 37.41% 
at high concentrations and that (11) inhibits by 14.64% at the same high 
concentrations. The estimated Ki's for (10) and (11) are 2.1 mM and 5.3 mM 
respectively, neither are potent inhibitors.
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CHAPTER ONE
INTRODUCTION
Chapter 1: Introduction
1.0 INTRODUCTION
The isolation and identification of adenoviruses as distinct viral agents was 
achieved in 1953 by two groups who independently recognised their 
appearance in tissue cultures from different tissue sourcesT Rowe et al. were 
evaluating tonsil and adenoidal tissue, removed from children, for the growth 
of polio viruses.2 They observed that a transmissible agent was causing 
cytopathic degeneration of epithelial like cells in uninoculated cultures after a 
prolonged incubation, they coined the agent responsible for this toxicity 
"Adenoid-Degenerating Agent". Hilleman and Werner recovered similar 
cytopathic agents from respiratory secretions in cell cultures of human upper 
respiratory tissue taken from febrile military personnel during an epidemic of 
an influenza-type respiratory disease, These agents were coined - "Acute 
Respiratory Disease" (ARD) agents. It was later discovered that there were 
multiple serotypes of these agents and that the initial serotypes were 
antigenetically related by a cross reacting family antigen which gave rise to 
antibodies detectable by compliment fixation.^
The nomenclature of adenoviruses was clarified and adopted in 1956.^ The 
Commission of Acute Respiratory Diseases of the U.S. Armed Forces 
confirmed that adenoviruses were the cause of the majority of acute febrile 
respiratory syndromes amongst military recruits. Epidemics of ARD were 
well documented in World War II and occurred almost exclusively in new 
recruits during the winter months, seasoned personnel who were in contact 
with the recruits were not infected nor were college students under similar 
c o n d i t i o n s ,  i ’6 This suggested that the factors of crowded sleeping conditions, 
fatigue and humid localised environments of barracks provided the ideal set of 
circumstances for wide spread infection. Controlled studies of routes of 
infection for ARD's have shown that aerosolised virus inhaled by volunteers
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produced the disease whereas application to the mouth, nasal mucosa or the 
intestine did not. Considering that ARD affected 80% of new recruits with 
20% - 40% being hospitalised, it is little wonder that the military expressed 
such an interest in the early findings and studies on adenoviruses. The 
symptoms of ARD had been recognised for up to one hundred years before 
the discovery of this new group of viruses and, indeed, German clinicians in 
the 1920's isolated a distinct clinical entity from outbreaks of epidemic 
keratoconjunctivitis which were now able to be identified as adenoviruses.^
Adenoviruses belong to the adenoviridae family and are divided into two 
genera; aviaadenovirus and mastoadenovirus. 8 Although there is a broad 
antigenic cross-reactivity within each of the genera, there is no common 
antigen that characterises the whole family. The mastoadenovirus genus 
include human, simian, bovine, equine, porcine, ovine, canine and opossum 
viruses. Human adenoviruses have been divided into six groups comprising 
some 47 serotypes.^
1.1 STRUCTURE OF THE VIRUS
Adenoviruses are nonenveloped, regular icosahedrons (20 equilateral 
triangular surfaces and 12 vertices) that are 60 to 90 nm in diameter. Each 
vertex has a fibre projecting from it and the length of this fibre varies with 
the serotype. The viral particle in its entirety is a large macromolecular 
assembly composed of at least 11 different structural proteins and a linear 
double-stranded DNA genome. The total mass of the particle is 150 MDa, 
which is roughly 18 times the mass of the picornaviruses and 6 times the mass 
of simian virus 40 (SV40), another DNA virus [See Figure 1, Page 3 ].!’10,11
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Figure 1: Electron Micrograph o f adenovirus 2.
The particle is defined as two compartments; i) the outer coat or capsid which 
is the icosahedron and, ii) the core which contains the DNA genome and is 
surrounded by the capsid.
The capsid is made up of 252 subunits or capsomeres. Of these capsomeres 
240 are hexons, which make up the faces and edges of the triangles, and 12 are 
pentons, which form the vertices. 12 The pentons consist of a penton base and a 
fibre which projects from these base, surrounding the individual pentons are 5 
hexons and around each hexon are 6 other hexons. Almost all of the structural 
data available for adenoviruses has been derived from detailed studies on 
serotypes 2 and 5, hence the following data are those which have been 
determined for Ad 2. The viral polypeptides that make up the virion have 
been numbered II to X (including Ilia) and terminal polypeptide. 11 
Polypeptides II, III, Ilia, IV, VI, VIII and IX make up the capsid, the 
remaining peptides plus the viral DNA make up the core [See Figure 3, Page 
7].
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1.1.1 Capsid Polypeptides
The hexon capsomere is a trimer of polypeptide II and is held together non- 
covalently, the penton base is probably a pentamer of polypeptide III and is 
non-covalently linked to the fibre which is made up of three molecules of 
polypeptide IV, this assembly of penton base and fibre is known as the penton 
c a p s o m e r e .  13,14 Polypeptides Ilia, VI, VIII and IX are all associated with 
these major proteins, polypeptides VI, VII and IX have been known to be 
associated with the hexon capsomere for sometime and more recently studies 
combining X-ray crystallography, electron microscopy and difference 
imaging have produced tentative spatial and structural assignments for all of 
these proteins. 11 Two monomers of Ilia penetrate the capsid and are 
sandwiched between hexons at adjacent facets, several copies of VI combine to 
form ring structures underneath the peripentonal hexons and polypeptide VIII 
is located on the inner surface of the hexon capsomere. The structure and 
location of peptide IX has been established more easily since it is located 
entirely on the surface of the capsid, 12 copies of IX monomers cluster into 4 
trimers and each monomer extends along a hexon-hexon interface or groove. 
This agrees with experimental findings which showed that mutant viruses 
lacking this protein still form intact virions but are less stable. The protein is 
synthesised late in infection and is not required for virion assembly so it may 
be assumed that it attaches to already assembled virions and stabilises them. 
This type of stabilising effect or "gluing together" of the major capsid proteins 
is also believed to be the function of proteins Ilia and VI and demonstrates the 
more highly complex structure of adenoviruses than that seen with smaller 
previously studied viruses. U
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1.1.2 Core Polypeptides
The absolute nucleo-protein core structure has not been established but several 
features have been deduced from studies of the disrupted virion. Polypeptides 
V and VII are rich in arginine like cell histones but, unlike histones, they also 
contain tryptophan. After disruption of the virion particle with either 5M 
urea, 10% pyridine, acetone or multiple freeze-thaw cycles these two 
polypeptides remain non-covalently linked to the viral DN A . 15,16 in each core 
there are 1,070 copies of protein VII and 180 copies of protein V, the exact 
function of these proteins is unclear, however, protein V can bind to a penton 
base and may therefore serve a positioning role in the packaging of the viral 
D N A . 17 It appears that polypeptide Ilia may serve a bridging function 
between the protein VIII of cores and the peripentonal hexons of the 
capsid. 11,17 The terminal polypeptide (TP) is covalently bound to the 5' ends 
of the double stranded viral D N A . 18 The core contains another protein - 
polypeptide X, previously termed p - which is also rich in arginine and 
histidine. This protein is probably the cleavage product of one of the larger 
core proteins. However, its precise location and function are not understood. 1^
1.1.3 Virion DNA
The viral DNA for Ad2 is 23.85 MDa and varies slightly in size between 
serotypes.20 it is approximately 11 mm in length and displays the unusual 
feature of the terminal polypeptide covalently linked to dCMP at each 5' end 
of the linear genome. 18,21 When the DNA molecules are released from 
virions (with 4M guanidine) they form circles due to non-covalent interactions 
between the terminal proteins at each end. 18 Adenovirus DNA also has 
inverted terminal redundancies at either end of each strand of DNA. The 
length of these repeats varies from 100 to 140 base pairs with the serotype. A
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consequence of this is that after the terminal proteins have been removed by 
proteolysis, the denatured single strands of Ad DNA can form circles by base 
pairing these terminal redundancies to form panhandle structures, and it may 
be that these are important for DNA replication [See Figure 2, Page 6].^2
virion
guonidinium. HClSOS
pro te in
C'BA'
C8A
dena tu reanneol
A A"
pronose
Î U
Figure 2: Scheme o f viral DNA digestion.
Partial nuclease digestion of adenovirus cores results in a diffuse band of DNA 
of approximately 150 base pairs, that is associated with six polypeptide VII 
proteins in a nucleosome-like structure. 19 Each of these structures is separated 
from the next by a variable length of DNA containing one molecule of 
polypeptide V. The length of the DNA spacer plus nucleosome is 
approximately 200 base pairs on average but, unlike cellular or SV40 
chromatin, the nucleosomes are irregularly placed on the DNA. The six copies 
of polypeptide VII that make up the nucleosome are arranged as three dimers 
and the 110 kDa moleculai* weight of this assembly is very similar to the 108
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kDa of the histone octomer in each chromatin nucleosome, however the spacer 
protein V is much larger than its histone equivalent. Various models of the 
core packaging have been proposed describing interactions with the faces or 
vertices of the virion. Although the structure has not been established, the 
DNA associated polypeptides have been given hypothetical locations [See 
Figure 3, Page 7].H»23 The viral DNA is probably compacted by about 5.5- 
fold in length by its association with these polypeptides. 19
CORE CAPSID
- i i Q
- I I I V
- I l ia  I
Terminal 
DNA------ - V I  #  
VIII m
Figure 3: Pictoral Representation o f Viral particle.
1.2 SUBGROUP AND SEROTYPE CLASSIFICATION
To date at least 5 methods of subdividing human adenoviruses into subgenera 
have been used [See Table 1, Page 8].T9 The first sub-classification was based
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on the haemagglutination reaction patterns with rat and rhesus monkey red 
blood c e l l s . 2 4  This method, which defines six groups (A-F), compares the 
extent and selectivity of haemagglutination induced in the two different types 
of cell as a result of adenovirus infection. With the discovery that Ad 12 could 
induce tumours in rodents a second sub-classification was developed as it was 
quickly realised that adenoviruses varied considerably in their oncogenic 
potential and with few exceptions the groups defined by haemagglutination 
patterns displayed similar oncogenic p r o p e r t i e s . 4 .2 5
The current method of classification uses DNA base composition and 
homology.
Sub­
genus Serotype
DNA
%
G+C
% Rat
Haemagglutination 
Rhesus Monkey Oncogenicity
A 12,18,31 48-69 48 +/- High
B1
B2
3,7,16,21
14,11,34,35
89-94 51 - + Weak
C 1,2,5,6 99-100 58 +/- Nil
D
8-10,13,15,17
19,20,22-30
32,33,36,37
38,39,42-47
94-99 58 + +/0 Nil
E 4 58 +/- Nil
F 40,41 62-69 52 + Nil
Table 1: Classification o f currently recognised adenovirus serotypes.
Base composition refers to the percentage G+C content and homology refers 
to conserved sequences within a single group of serotypes.26 Group A 
adenoviruses have a comparatively low G+C content of 48% and it was
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thought that this was related to tumour induction and that the high G+C 
content (58%) of group C resulted in non-oncogenic viruses. However, this 
generalisation does not hold for the simian viruses and is, therefore, probably 
indicative of the genetic origin or evolutionary variation of a serotype. 
Homology within single groups, measured by DNA-DNA hybridisation, is 
greater than 85% except for group A which is 48-69% between its three 
m e m b e r s . 27,2 8  Across different groups there is less than 20% homology as 
determined by the hybrid method. Divergence of the DNA sequence between 
members of a group is at a maximum in the regions coding for the hexon 
capsomere and the fibre. These are the capsid proteins to which many of the 
hosts antibodies are directed. 27
Most of the adenovirus serotypes show distinct patterns for DNA cleavage 
fragments after digestion of the viral DNA by restriction endonucleases. Thus, 
serotypes have been grouped by common, related fragments. This method has 
also been particularly useful in classifying Ad isolates removed from clinical 
s p e c i m e n s . 2 9  Another criterion for group classification is the size of the virion 
polypeptides using S.odium Dodecyl Sulphate - PolyAcrylam ide G_el 
Electrophoresis (SDS-PAGE).
Since these different techniques rely on the properties of many different 
chemical and biochemical characteristics of the various serotypes, nowadays 
multiple serologic and biochemical techniques are used for the classification of 
new adenovirus isolates.
1.3 ADENOVIRUS REPLICATION
The study of lytic infection by adenoviruses has been aided by two major 
factors associated with adenoviruses. First, most adenoviruses grow well in
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suspension cultures of HeLa or KB cells and, second, human adenoviruses 
remain cell-associated well after the production of new virions.30 HeLa cells 
are a continuous, immortal epithelial cell line removed from a cervical 
tumour from Henrietta Lacks in 1951, KB cells are also a continuous epithelial 
cell line and both types of cell are used extensively in microbiology as 
standard cell lines. This makes it possible to concentrate large volumes of 
virus infected cells and study their biochemistry at high multiplicity ensuring 
synchronicity of infection and of subsequent biochemical events in the 
replicative pathway. The replicative cycle consists of several stages; invasion 
of the cell and transport to the nucleus, onset of replication (termed Early (E) 
Phase), viral DNA replication, start of Late (L) Phase, virion assembly and 
cell lysis with the release of new virus particles, l Early Phase and Late Phase 
are defined as the events which occur before and after viral DNA replication 
respectively but these are not absolute definitions. Indeed some polypeptides 
that are synthesised early are also synthesised late and vice versa.^l
The virus is adsorbed slowly onto the cell surface via the fibre attaching to 
specific receptors on the cell m e m b r a n e . 9 . 32 This fibre-cell receptor 
interaction does not involve carbohydrate recognition and is in fact an amino 
acid interaction.33 The virion is then phagocytosed into receptosomes over 
several hours.9 The penton polypeptide lowers the pH within the receptosome 
to 5.5 which probably serves to alter the configuration of the virion and 
results in rupture of the phagocyte membrane and release into the cytoplasm 
[See Scheme 1, Page 11]. 1 In vitro studies have shown that the cytoplasmic 
virions are attached to microtubules by the hexon and the process of transport 
to the nucleus probably involves these structures.
Chapter 1: Introduction 11
Ciii)
<lv)
Scheme 1: Cartoon showing the adsorbtion o f the virus into a cell, (i) Virus
attachment to cell membrane receptors; (ii) + (Hi) Phagocytosis o f particle 
into cell receptosome; (iv) Penton lowers pH to 5.5 and virus released into 
cytoplasm.
The virus is uncoated and the viral core enters the nucleus, many of the viral 
proteins are left in the cytoplasm.34 Release into the cytoplasm, transport and 
insertion into the nucleus takes place over 1-2 hours. After uncoating and 
before the onset of replication the virus cannot be recognised cytopathically or 
antigenically nor can it be observed microscopically.^ This is the eclipse phase
Chapter 1: Introduction 12
which is quite long and therefore the time taken for adenovirus infection to be 
detected in cell culture is also long. The early phase of replication may be 
further subdivided into immediate early (IE) and early (E). Before DNA 
replication commences the IE and E mRNA's are transcribed. This 
transcription takes place from 5 distinct regions of the genome.9 The 
immediate early gene products promote and enhance the transcription of the 
early genes. These early genes are translated from early mRNA into early 
proteins required to initiate viral DNA replication. Of these delayed early 
mRNA molecules is E2B, which codes for a 140 kDa DNA polymerase and an 
80 kDa precursor to the terminal protein.35 Viral DNA replication 
commences in the nucleus approximately 6-8 h post-infection signifying the 
end of the early phase. By 20 h DNA replication is at a peak rate, stopping 
after a further 4 h signifying the start of the late phase.^ The synthesis of host 
cell DNA is reduced by more than 90% after the onset of viral DNA 
replication i.e. 6-8 h post-infection.36,37 The new DNA strand elongates in a 
continuous manner from the 5' end to the 3' end, i.e. one parent strand is 
replicated whilst the other is displaced and free. This single strand of free 
DNA spontaneously circularises into the panhandle structure previously 
described. 1 From this panhandle a second daughter strand elongates from the 
5' end to the 3' end separating and replicating the panhandle and further into 
the "pan" to form a second molecule of viral DNA. The Terminal Protein 
which is covalently linked to the first nucleic acid serves as a primer for DNA 
replication initiation so both the 140 kDa DNA polymerase and the 80 kDa 
pTP coded by E2B are required in the first instance for replication. With the 
onset of viral DNA synthesis comes the transfer from early phase to late 
phase. During this phase the majority of the viral polypeptides are synthesised 
and the synthesis of host macromolecules is compromised. The late viral 
polypeptides are synthesised at a maximum at 20 h post-infection, host protein 
synthesis having been halted for some 4 h previously or 16 h post-infection.9
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This inhibition of host macromolecular synthesis may be partially explained 
by the depletion of host mRNA on cytoplasmic ribosomes. However, primary 
transcription of host cell RNA is still active in the nucleus. There is a 
breakdown of the transport of these cell mRNA precursors to the cytoplasm. 
As there is no rapid breakdown of cell mRNA on ribosomes, it is still difficult 
to explain the cessation of host protein synthesis in terms of the inhibition of 
transport or processing of nuclear transcripts. 1 These features, therefore, 
point to some form of translational control. The inhibition of new ribosome 
formation is also profound and similar to that caused by inhibitors of protein 
synthesis. This process of host translation shut down in the late phase has been 
shown to prevent cell division and promote destruction of the intermediate 
filament network.
Many mRNA molecules transcribed in the early phase are also transcribed in 
the late phase. The structural viral polypeptides are mainly synthesised in the 
late phase but IVa2 and IX are also synthesised early. In the late phases some 
of the transcripts from L2 and L3 have been found early, particularly the L3 
23 kDa proteinase which is always found in small amounts early in infection.
1.3.1 Assembly of Virions
Virion assembly takes place in the nucleus but the requisite capsomere 
structures are formed in the cytoplasm.38 The first capsomere to be assembled 
is the hexon, a trimer of identical polypeptides held together non-covalently. 
This assemblage occurs with the assistance of a 100 kDa non-structural viral 
protein and occurs in minutes.39 The hexons then self assemble through the 
formation of ninemers into the 20 faces of an empty shell capsid. The penton 
capsomere assembles from the penton base pentamer and three fihre 
polypeptides over a somewhat more prolonged period. The first 25% of
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pentons are assembled within 20 min with the rest forming over some 10 h.38 
The details of penton assembly are not clear. However, it is likely that many 
are not incorporated into the capsid until a later stage.
The next recognisable stage is the capsid or light intermediate stage.40 During 
this phase the capsid associated polypeptides VI and VIII become incorporated 
into the hexon shell as their precursors (pVI and pVIII) along with Ilia and a 
50 kDa and 39 kDa viral protein. The 50 and 39 kDa polypeptides act as 
scaffolds in the formation of the light capsid and are removed shortly 
a f t e r .  1 >40 Next comes the insertion of the viral DNA with the terminal protein 
precursor (pTP) then come the core polypeptides V and precursor VII. Since 
it is believed that the penton capsomere has not been fully incorporated at this 
point the DNA presumably inserts through one of the open 12 vertices. 
Protein IX becomes associated at this stage also. This state is known as the 
young virion, maturation from young to mature occurs with the action of the 
L3 23 kDa proteinase cleaving the precursor proteins into their active or 
mature forms in the core.41 The fragments of these polypeptides pVI, pVII, 
pVIII and pTP are degraded or ejected as the particle firms up its mature 
conformation with final association and consolidation of the pentons. The 
proteinase contains over 200 amino acid residues and its sequence is highly 
conserved between serotypes (72% between Ad2 and Ad4). Sequence analysis 
has shown that there is no primary structure homology with any other known 
proteinases, therefore, this proteinase probably represents a new class of 
enzyme.42 Only about 15% of new viral proteins and DNA are incorporated 
into virions.9 The viral material not incorporated acts to promote the 
cytopathic effect (CPE) by shutting off host macromolecular synthesis and by 
disruption of both the cytokeratin network of the cytoplasm and the nuclear 
m e m b r a n e .  1 > 9 ,4 3 ,4 4  This results in cells ceasing to divide, subsequent cell 
death and lysis releasing the new virus particles. The penton capsomere is
Chapter 1: Introduction 15
directly toxic to cells other than those infected with a d e n o v i r u s . ! >9 Although 
its role is not clear in this area, pentons have been found in the blood of fatal 
cases of adenovirus related p n e u m o n i a . 4 5
1.4 CLINICAL SYNDROMES
Adenoviruses infect and replicate in a wide range of tissues producing many 
different diseases most of which are subclinical [See Tables 2 and 3, Pages 23 
and 24].9 These tissues include, most commonly, the respiratory tract, eye, 
gastrointestinal tract and b l a d d e r . 4 5  Sporadically they cause disease in more 
remote organs, the central nervous system for instance, where 
meningoencephalitis may be induced and complicated by an adenovirus 
infection.9 Adenovirus infections occur world-wide and are species specific 
with patterns of infection varying from sporadic to epidemic. The virus is 
spread via respiratory or ocular secretions and by the faeco-oral route in 
young children.9 Other means of trans-infection can be swimming pools and 
improperly sterilised ocular equipment. In 40-60% of young children the most 
common antibodies present are to types 1, 2 & 5 which are endemic in most 
populations, but few have been exposed to types 3, 4 or 7 and these are the 
serotypes responsible for epidemic infections.9
1.4.1 R espiratory  Diseases
Adenoviruses are responsible for 5% of the acute respiratory disease in young 
children with symptoms including nasal congestion and c o u g h i n g . 4 6  i n  
addition to these symptoms there are often further effects such as general 
malaise, fever, chill and headache. Isolated cases are often indistinguishable 
from influenza, parainfluenza and other viral respiratory infections. Types 1, 
2, 5 and 6  (group C or HA group III) and occasionally type 3 (group B or HA
Chapter 1: Introduction 16
group I) are the most common causes and are endemic in most populations. 
When conjunctivitis in one or both eyes is coupled with the above symptoms 
the disease is known as pharyngoconjunctival fever.47 This is usually mild and 
most commonly caused by type 3 but types 7 and 14 within the same HA 
group have been found in such patients.48 In more severe instances pneumonia 
may be the result and adenoviruses account for approximately 1 0 % of 
childhood pneumonias .45 These lower respiratory infections tend to be fairly 
trivial but where there have been epidemics of Ad 7, mortality rates were 
considerable. Of those who recover bronchictasis may clinically manifest itself 
years after primary infection. Acute respiratory disease (ARD) of military 
recruits as described previously (Page 1) is similar to that of the respiratory 
infection of children. Ad 4 and Ad 7 are responsible and less often Ad 3, this 
syndrome occurs under conditions of fatigue and crowding which is 
characteristic in young military recruits.48
Adenovirus infection has been linked in many cases to cases of whooping 
cough and some believe that it is this rather than Bordetella Pertussis that is 
responsible.49 Ad 5 was isolated from multiple organs of a patient with 
whooping cough and lymphocytosis that ended fatally, however, adenoviruses 
alone are probably not responsible for the syndrome. As with many other 
adenovirus infections, symptoms related to the virus appear with concurrent 
infection by other pathogens. Latency has been shown to be prolonged and 
often disease never results, except in the case of immunosuppression by other 
infections.50
1.4.2 O cular Diseases
Swimming Pool conjunctivitis is probably most commonly due to adenoviruses 
and acute follicular conjunctivitis can occur with respiratory-pharyngeal
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syndrome or by itself. Significant preauricular lymphadenopathy often 
accompanies this d i s e a s e . 4 7 , 5 1  This is a rather mild disease and complete 
recovery is the most common result. Infection may be sporadic and affect only 
family members or in the cases where the source is a lake or swimming pool 
the disease can be widespread amongst children and young adults.45 The 
water-borne outbreaks occur almost entirely during the summer months and 
are caused by A d  3 and 7 although a wide number of serotypes spanning 
groups B, C, D and E or HA groups I, II and III have been associated with this 
sy n d ro m e .51 A more serious, highly contagious disease caused by 
adenoviruses is epidemic keratoconjunctivitis (EKC).45 This was identified as 
a clinical entity before adenoviruses and occurred amongst German workers at 
the turn of the century. It was subsequently found in ship-yard workers in the 
continental United States and Hawaii and coined "Ship-yard Eye".7 It was 
almost certainly transferred through the medical facilities that catered for 
trauma to the eyes of workers. Symptoms include follicular conjunctivitis, 
edema of the eyelids, pain, photophobia and lacrimation. The disease is often 
unilateral with preauricular lymph node hypertrophy. In some instances a 
haemorrhagic conjunctivitis develops which must be distinguished from the 
enterovirus 70 acute haemorrhagic conjunctivitis.45 EKC was originally 
caused by A d  8 then through the 1970's A d  19 was more common and since 
1977 A d  37 has been the prominent p r o g e n i t o r . 5 2 , 5 3  eKC has occurred as an 
epidemic in parts of Taiwan, Vietnam and Japan during the autumn months 
and has accompanied endemic trachoma in Saudi A r a b i a . 4 5 , 5 4
1.4.3 Renal Diseases
American children rarely have type 8 antibodies whereas half the Japanese or 
Taiwanese children do. Acute haemorrhagic cystitis is an illness that occurs 
almost solely in male children and has been linked to adenovirus type 11. The
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problem with this infection is its confusion with more serious diseases of the 
kidney such as glomerulonephritis.45 Type 21 can also cause haemorrhagic 
cystitis and belongs to the same group as type 11, group B or HA group I. 
Cases of acute haemorrhagic cystitis in Japanese males between the ages of 6  
and 15 showed adenoviruses in isolates from urine in approximately 70% of 
patients. In contrast, under the same study conditions, only 20% of 
haemorrhagic cystitis in the U.S.A. could be linked to adenovirus infection. 
Following renal transplantation and its accompanying immunosuppression 
three cases have been reported of Ad 11 acute haemorrhagic cystitis.45 in one 
of these the infection was introduced with the new kidney, but this is not a 
typical complication of renal transplants and as previously described 
adenoviruses are opportunistic on hosts with suppressed immunity. 
Coincidentally two other group B serotypes 34 and 35 were first isolated from 
renal transplant patients. Type 34 from urine and 35 from kidney and lung 
tissue.55 Whilst neither gave rise to haemorrhagic cystitis. Ad 35 undoubtedly 
contributed to the pneumonia which killed the patient.
1.4.4 Diseases of the C entral Nervous System
Although adenoviruses are not commonly found in the cerebrospinal fluid, 
some cases in which serotypes have been isolated from the brain and 
cerebrospinal fluid have been reported (types 3, 5, 6 , 7, 7A, 12 and 32). For 
instance, a patient receiving chemotherapy for the treatment of a malignant 
lymphoma, and consequently immunosuppressed, had an adenovirus type 32 
isolated from the brain at post-m ortem .5 6 Other instances of 
meningoencephalitis have been reported in children, these have been 
particularly associated with epidemic adenovirus type 7 pneumonia. In 
addition an isolated case of sudden deafness was linked to an adenovirus type 3 
infection of the nasopharynx.45
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1.4.5 D iarrhoea and In testinal Diseases
Adenoviruses and diarrhoea have had a complicated history which has recently 
been clarified. Since it had been well established that many adenovirus 
serotypes replicate efficiently in the intestine, research was undertaken in 
order to identify the connection between adenovirus infection and 
d i a r r h o e a . 5 7 , 5 8  Attempts to correlate adenovirus growth from stool with 
clinical illness did not prove to be conclusive as just as many adenovirus 
isolates were found in the stools of controls as those from subjects with 
diarrhoea. So although young children with systemic adenovirus infections can 
often develop diarrhoea these instances are probably no more common than 
that caused by any other systemic infection.
Following the discovery of "non-cultivable" adenoviruses by electron 
microscopy of stool smears from children suffering gastro-enteritis, research 
has re-examined the possibility that these were the cause of infantile gastro­
enteritis.58 Two new, different serotypes of the human adenovirus, known as 
the enteric adenoviruses (EAd), have been strongly associated with diarrhoea 
and acute gastrointestinal disease (serotypes 40 and 41). Of 27 hospitalised 
young children with acute gastrointestinal disease, 14 were related to enteric 
adenoviruses and it was suggested that the respiratory symptoms also observed 
were a major facet of the clinical manifestations. The incidence of adenovirus 
related gastro-enteritis is approximately 1 2 % of all the intestinal infections in 
young children. Over some population groups 50% of children aged 4 express 
antibodies to these enteric adenoviruses.59
Intussusception, another intestinal syndrome, has been associated in some cases 
to adenovirus i n f e c t i o n . 4 5 , 6 0  Adenoviruses have heen isolated from the 
infected lymph nodes removed at surgery and also from stool cultures. Two
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explanations have been proposed; i) the telescoping bowel characteristic may 
be caused by mesenteric adenitis acting as a lead point to the obstruction and 
ii) that the hyper irritability of the small intestine might be caused by 
adenovirus infection and thus may lead to the intussusception. However, most 
of the patients with intussusception show no signs of adenovirus infection. 
Therefore, adenoviruses are probably one of many factors which might lead 
to this syndrome.61
Interestingly A-gliadin, a major component of oc-gliadin which is known to 
activate coeliac disease, possesses considerable structural homology to the 
adenovirus type 12 ElB protein. Coupled with the finding that most patients 
with coeliac disease had indeed suffered prior Ad 12 infection, in contrast to 
the controls, these findings suggest that the type 12 viral protein ElB may act 
as a trigger inducing the pathogenesis of coeliac d i s e a s e . 6 2
1.4.6 Im m unocom prom ised Patients
Adenovirus infections amongst immunocompromised patients, whilst not as 
common as the various herpes virus infections, have contributed to the 
mortality of these patients.
From 1967 to 1978 at the UCLA Centre for the Health Sciences 15 
immunocompromised patients with typical endemic adenovirus infection were 
s tu d ie d .50 Bearing in mind that most of the population are infected with many 
different serotypes of adenovirus and have never manifested any clinical 
symptoms. Twelve of these patients suffered from pneumonia, 8 had hepatic 
abnormalities and 9 died of hepatic or respiratory failure. In only three 
instances was there evidence of other types of infection. In children the 
serotypes responsible were 1, 2, 5 and 6  and in adults, type 4. It is obvious
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from these data that, whilst immunocompromised patients are no more 
susceptible to adenovirus infection, the consequences of such infections are 
much more serious and in the majority of cases fatal. Over recent years the 
obvious group to suffer from immunity suppression are AIDS patients, 
indeed, 12% of the AIDS patients at UCLA displayed adenoviruses in their 
urine. As mentioned previously (Page 14) restriction endonuclease digestion 
of viral DNA can be used to group serotypes by their common cleavage 
fragments. This technique was used to identify the serotypes isolated from 
AIDS patients urine and showed that more than 85% of the viral DNA 
fragments isolated were attributable to Ad 35. Also there appears to be some 
recombination across serotypes as observed from the haemagglutination 
patterns of the AIDS urine isolates.63 These recombinations are poorly 
understood and only occur in AIDS patients to date.
Another group who suffer immunity suppresion are patients who have 
undergone bone marrow transplants. These patients have also had similar 
group B adenoviruses isolated from their urine but this is not as common as in 
AIDS patients. AIDS patients have also had many group D adenoviruses 
isolated from stool and rectal swabs.64
1.4.7 Latency and M alignancy
The latency of adenoviruses has been well established, indeed, it was a 
consequence of this property that led to the discovery of adenoviruses in 
adenoidal t i s s u e . ! >2 Adenoviruses were shown to persist in healthy hosts up to 
2 years after initial infection. B lymphocytes in particular have been suggested 
as helping to maintain latency by several groups who have shown low levels of 
viral DNA incorporated in peripheral blood lymphocytes.65 A confirmation 
of latency in tonsil tissue was made by the demonstration that adenovirus
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nucleic acid sequences were present in this tissue but without infectious 
v i r u s . 6 6  However, the ultimate example of latency which would be the stable 
integration of sequences of viral DNA in covalent linkage with the host 
chromosome has not been observed. It has been clearly established that some 
serotypes are highly oncogenic in animals, particularly types 1 2 , 18 and 31, 
but attempts to link human tumours to adenovirus infection have been 
u n s u c c e s s f u l . 6 7  However, subject to confirmation is the finding by one 
research group of Ad nucleic acid in neurogenic tumours.
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Site of infection/ disease Serotypes
RESPIRATORY TRACT
Acute febrile pharyngitis 1,2,3,5,7
Adenopharyngoconjunctival fever 3,7
Acute respiratory disease of military recruits 4,7,14,21
Pneumonia 1,2,3,7
Pertussis-like syndrome 5
EYE
Follicular conjunctivitis 3,4,11
Epidemic keratoconjunctivitis 8,19,37
KIDNEY
Acute haemorrhagic cystitis 11,21
CENTRAL NERVOUS SYSTEM
Meningitis 3,7
Subacute focal encephalitis
GUT
Diarrhoea 40,41
Intussusception 1,2,5
Coeliac disease (?)
OTHER
Rubelliform rash
Acute febrile polyarthritis
Table 2: The clinical syndromes produced by adenoviruses and the most 
common serotypes associated with them.
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Disease Individuals most at risk
Principal
serotypes
Acute febrile pharyngitis Infants, young children 1,2,3,5,6,7
Pharyngoconjunctival fever School-age children 3,7,14
Acute respiratory disease Military recruits 3,4,7,14,21
Pneumonia Infants, young children 1,2,3,7
Pneumonia Military recruits 4,7
Epidemic keratoconjunctivitis Any age group 8,11,19,37
Pertussis-like syndrome Infants, young children 5
Acute haemorrhagic cystitis Infants, young children 11,21
Gastroenteritis Infants, young children 40,41
Hepatitis Infants and children with liver 
transplants
1,2,5
Persistence of virus in urinary 
tract
AIDS, other immunosuppression 
and bone marrow transplant 
recipients
34,35
Table 3: Illnesses associated with adenovirus infections, the groups most at 
risk and the most common serotypes responsible.
1.5 THE ADENOVIRUS SEROTYPE 2 L3 23 kDa PROTEINASE:
The 23 kDa proteinase is a virally encoded enzyme and has been the subject of 
much discussion and research effort since its putative identification and the 
observation of its varied f u n c t i o n s . 4 3 ,44,68-78 Many viruses encode for their 
own proteinases, this "self-encoding" is not uncommon in D N A  viruses, 
occurs in all retroviruses and in many R N A  v iru se s .79 Proteolytic processing 
in the life cycle of a large number of viruses is an absolute requirement for 
successful replication, maturation and spread of new infectious virus
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p a r t i c l e s . 79 Proteolytic enzymes are normally thought of as serving 
degradative roles but proteolysis is involved in a productive manner in several 
important biosynthetic processes such as blood coagulation, fertilisation and 
the production of peptide h o r m o n e s .79 However, these proteolytic enzymes 
are subject to strict regulation mechanisms as over-enthusiastic digestion 
would prove disastrous to the organism. This requirement for regulation and 
specificity for the types of peptide bonds to be hydrolysed is nowhere more 
evident than in the polypeptide processing in v i r u s e s .79 Cleavages catalysed by 
virus encoded proteinases are particularly complex and occur by a variety of 
mechanisms serving diverse functions. One of their major functions is to 
facilitate the assembly of new virus particles principally by proteolytic 
processing of precursor polypeptides into the requisite forms for capsid 
formation and DNA encapsidation. Other functions include a role in the 
uncoating of virus particles in the newly infected cells and contributing to the 
cytopathic effect by degrading structural proteins within the host cell.^0  
Therefore, the extremely high substrate selectivity and specificity of peptide 
bond hydrolysis is inherently necessary for the successful propagation of viral 
infection. This strict specificity also removes viral proteinases from regulation 
by host cell inhibitors. It is this characteristic, coupled with their pivotal role 
in infection that sets up virally encoded proteinases as potential therapeutic 
targets. The rationale being that a synthetic compound which specifically 
inhibits the action of the viral proteinase would, by definition, be unlikely to 
interfere with similar host enzymes offering an extremely attractive 
opportunity for the development of anti-viral drugs. Obviously before 
potential inhibitors or therapeutic drugs can be designed or synthesised the 
precise chemical mechanism of the enzyme must be elucidated. In order to 
determine the chemical mechanism, the residues which are actively involved in 
the reaction must be known as does their spatial arrangement and their 
electronic properties. As previously mentioned the L3 23 kDa proteinase
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amino acid sequence displays little homology with any known enzymes and as 
such probably represents a new class of enzyme or at least presents a novel 
mechanistic problem.
At the present time there are four classes of proteinase which are defined by 
the residues involved in the proteolysis. Serine proteinases and cysteine (thiol) 
proteinases are so-called because the active site nucleophile is a serine and a 
cysteine residue, respectively. The nomenclature for the other two classes 
refers to the group in the acitve site which polarises the carbonyl of the 
substrate in order to facilitate nucleophilic attack and these are the Acid 
proteinases and Metalloproteinases [See Scheme 2, Page 26].
Nu
Scheme 2: Generalised mechanism o f enzyme catalysed peptide bond 
hydrolysis. Where fo r  serine and cysteine proteinases, Nu = oxygen and 
sulphur respectively and for acid and métallo- proteinases, 5+ = carboxylate 
and a metal ion respectively.
Examples of enzymes which belong to these four classes are; chymotrypsin 
(serine) [See Scheme 3, Page 27], papain (cysteine), pepsin (acid) and 
carboxypeptidase A (metalloproteinase, Mn+).
i i
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Scheme 3: Detailed scheme o f enzymatic peptide hydrolysis, in this case the 
enzyme is the serine proteinase chymotrypsin.
Attempts to classify the enzyme as either a serine or a cysteine proteinase have 
recently been clarified by site directed m u t a g e n e s i s 74,75 Site directed 
mutagenesis on its own is not sufficient to prove one hypothesis or the other 
since by its very application one alters the primary structure of the protein 
and therefore probably the secondary structure and possibly the tertiary 
structure of that protein. However, the results of the SDM experiments 
together with an increasing plethora of evidence strongly suggesting that the 
enzyme is a cysteine type proteinase makes the case for cysteine type catalysis 
very strong indeed. The evidence that had been presented classifying the L3 23 
kDa proteinase as a serine proteinase was based on inhibitor studies which 
showed that diisopropylfluorophosphate, a compound which reacts covalently
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with the active site of serine proteinases, blocked the activity of this e n z y m e .68 
However, on it own this is not sufficient confirmatory evidence since it is 
known that other cysteine proteinases, notably carboxypeptidase B and the 
neutral cytosolic proteinase that cleaves the B chain of insulin, are inhibited by 
both cysteine proteinase inhibitors and métallo proteinase inhibitors.^! Further 
another group of cysteine proteinases, lysosomal catheptic carboxypeptidase A 
and prolylendopeptidase, are inhibited by both cysteine proteinase inhibitors 
and serine proteinase inhibitors.81 Therefore classification on this criterion 
alone can be erroneous. However, the grounds for this classification lay not 
only in the inhibition by DFP but with the additional information that 
mercaptoethanol had a negative effect on c a ta ly s is .68 This certainly is 
uncharacteristic of cysteine proteinases as very many of the previously studied 
cysteine proteinases, the papains and cathepsins, are activated by reducing 
agents [See Scheme 4, Page 28].83 This apparent contradiction will be further 
discussed as part of the novel mechanism of this enzyme.
‘159
RSHS H \
36,
Scheme 4; Conversion o f the catalytically inactive propapain to the active 
enzyme, papain, by the action o f a low molecular weight thiol
1,5.1 Sum m ary of Some C haracteristics of Cysteine Proteinases
Cysteine proteinases, previously known as thiol proteinases, are that group of 
endopeptidases whose members rely on the thiol group of a cysteine residue 
for catalytic activity [See Scheme 2, Page 26].80 The cysteine proteinases
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which have been extensively studied all appear to contain a thiol-imidazole 
interactive system within the active site and this is probably a common motif 
throughout the group. This system most probably functions as the 
thiolate/imidazolium (S~/ImH+) ion pair, the thiolate anion being transiently 
acylated during catalysis, assisted by general acid catalysis from the 
imidazolium ion [See Scheme 6 , Page 44]. The ion pair produced by the 
protonic dissociation with a pKa 3-4 could be a common feature of the group 
and localised low pH environments within enzymes are common. A variable 
feature between members of the group is another pH dependant process which 
endows or enhances the ion pair catalytic competence. This second pH 
dependant event which is probably involved in the control of the ion pair 
geometry is required to separate the components of this intimate, mutually- 
solvated, ion pair at some point of the acylation process of catalysis to permit 
them to act as nucleophile and general acid catalyst. Interestingly in the 
cysteine proteinases papain and ficin the residue on the N-terminal side to the 
active site histidine is aspartic acid. In cathepsin B, streptococcal proteinase 
and calpain I it is glycine and in cathepsin H it is asparagine. It is further 
interesting to note that the residue adjacent to the catalytic cysteine residue in 
streptococcal proteinase is histidine and in calpain I is aspartate. The presence 
of these charges at or around the active site are probably responsible for the 
variation in the second pH dependant event and contribute to the minor 
reactivity differences of cysteine proteinase S~/ImH+ catalytic systems.
Cysteine proteinases have been isolated from a wide variety of biological 
sources spanning plants, animals (including humans, rats, cattle and poultry) 
and bacteria. Almost all cysteine proteinases are small enzymes in the range 
2 0 - 3 5  kDa. The molecular weights of papain and actinidin are 2 3 . 3 5  and 2 3 . 5  
kDa r e s p e c t i v e l y . 8 1 , 8 3  The calpains - 1 1 0  kDa and clostripain - 5 5  kDa are two 
examples of cysteine proteinases that are significantly larger. Both enzymes
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are composed of two subunits, one light and one heavy. The calpains are 
heterodimers, both subunits contain potential Ca^+ binding sites and it is the 
heavy subunit that contains the active site. Clostripain is composed of two 
chains linked by non-covalent forces, it is interesting to note that the lighter 
(15.4 kDa) of the chains is terminated by an arginine residue. It appears 
probable that the chains originate from a single chain precursor given that 
clostripain has a marked specificity for cleavage at arginine residues. 
Isoelectric points of cysteine proteinases span a range from 3 to almost 12. 
Most are acidic to neutral including actinidin (pi 3.1) fruit bromelain, 
clostripain and cathepsin B (pi 4.5-5.5) the other cathepsins (pi 6-7). Ficin, 
stem bromelain and calotropin DI are all basic pi >8.75 and the most basic is 
the papaya proteinase W (pi 11.7).
In biological systems where cysteine proteinases occur naturally i.e. 
manufactured by the host as in the examples above (papain, actinidin, the 
calpains, clostripain, fruit bromelain, the cathepsins, ficin, stem bromelain, 
calotropin DI and papaya proteinase W), their principle function is the 
regulation of intracellular and extracellular protein turnover. 8 3 Cysteine 
proteinases are responsible for over 50% of intracellular proteolysis, in 
particular cathepsin L alone was found to be responsible for 50-60% of the 
proteolytic activity of hepatic lysosomes at pH 6.0.81 Cathepsins are 
distributed throughout many tissues (liver, spleen, kidneys, lungs, skeletal 
muscle and brain) and are associated with various inflammatory reactions and 
diseases where their activity increases dramatically. In developing muscular 
dystrophy there is an increase in the number of cysteine proteinase containing 
lysosomes near the degenerating myofibrils of the muscle and increased 
cathepsin B activity has been reported in the macrophages of patients with 
rheumatoid arthritis.84 Cathepsin B and cathepsin B-like activity has been 
observed in various forms of cancer cells.85 A cathepsin B-like enzyme is
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selectively secreted by malignant human breast tumours and a similar enzyme 
which is immunologically related to cathepsin B is found in the ascitic fluid 
from patients with neoplasia.81 In the plasma membranes and nuclei of 
neoplastic cervical cells a heat and alkali stable cathepsin B-like enzyme has 
been detected. Also reported is an increase in the cathepsin B activity in a B 16 
melanoma variant and it is probably the case that cathepsin B release from 
tumour cells aids invasion and extravasation of tumours. 86
The preceding group of cysteine proteinases are known as the "Low Molecular 
Weight" lysosomal proteinases, a second group of cysteine proteinases are 
those referred to previously as the calpains (Page 29). These enzymes are 
dependent on specific cellular Ca^+ concentrations for their activity. Within 
this second subgroup there are a further 2 subdivisions. Calpain I and calpain
II. The calpains occur in almost all of the tissue cytoplasms studied to date and 
in many of the corresponding cell membranes. Their calcium dependency is 
poorly understood but it is known that calpain I is activated by micromolar 
concentrations of Ca^+ whilst calpain II requires millimolar concentrations for 
activity.83 Endogenous, specific protein inhibitors, calpastatins, occur as 
widely as the calpains themselves, and almost certainly constitute an 
irreversible intracellular regulatory system. It has been shown that calpastatin 
inhibits calpains I and II in the presence of Ca^+. The calpain-calpastatin 
complex does not associate in the absence of Ca^+ and dissociates if Ca^+ is 
removed from an existing complex. This suggests, therefore, that the calpains 
undergo a conformational change in the presence of Ca^+ resulting in the 
active form of the enzyme and it is this form of the enzyme to which the 
calpastatin binds. A calcium dependent proteinase regulator (CDPR) has been 
partially purified from bovine brain which stimulates calpain activity by up to 
25-fold but does not affect calcium sensitivity.87 The role of CDPR in the 
regulation of calpain activity is not understood. The biological role of calpains
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differs slightly from the lysosomal cysteine proteinases in that they are not 
major contributors to intracellular proteolysis. Their major functions include 
the regulation and activation of key metabolic enzymes, the modification of 
receptors by virtue of fluctuations in cell Ca^+ concentration and the 
degradation of cytoskeletal proteins and myofibrillar structures. It has been 
demonstrated that both calpains are responsible for the activation of protein 
kinase C and that calpain II modifies pyruvate kinase.88 Calpains are also 
involved in the degradation of smooth muscle tissue by their hydrolysis of 
myofibrils. Calpains have also been found in the retina where their function is 
to rapidly hydrolyse microtubule proteins along with actin and vimertin, two 
important cytoskeletal proteins in the eye.8 3 Proteolytic modification of 
receptors by calpains has been observed in a range of systems; the oestrogen 
receptor in the bovine uterus, the progesterone receptor of chick oviducts, the 
membrane neurotransmitter for glutamate in the rat hippocampus, the 
receptor for epidermal growth factor and others.89 Although the full 
physiological significance of all these processes is not fully understood it 
appears that calpains are not only involved in the regulation of these receptors 
and their efficient function but also in some cases the production of receptor 
fragments required for further biological processes.90 It also seems likely that 
calpains play a role in muscular degradation in muscular dystrophy as well as 
lysosomal proteinases by the degradation of the Z band, troponin I and C and 
the myosin heavy chains in muscle f i b r e s . 8 1 , 8 3
In addition to the hydrolysis of peptide bonds, cysteine proteinases catalyse the 
hydrolysis of esters, anilides, p-nitroanilides and p-nitrophenyl esters and 
these compounds are widely used mechanistic tools.83 The specificity of 
proteinases is described in terms of the Schechter and Berger model, in this 
model a polypeptide substrate is represented as:
j
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P 4 - P 3 - P 2 - P l - i - P ' i - P ' 2 . . . .
where P  represents an amino acid residue which binds to a particular region in 
the active centre (the enzyme subsites; S4-S3-S2-S1—ST-S'2....) and the long 
bond indicates the scissile bond of which ? i  provides the carboxyl moiety and 
P 'l  the amino moiety.91
CHAPTER TWO
RESULTS AND DISCUSSION
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2.0 RESULTS AND DISCUSSION
2.1 INTRODUCTION
The design and synthesis of potential inhibitors and chromophoric inhibitors 
of the adenovirus proteinase is important as they can provide valuable tools 
for the study of the chemical mechanism by which the enzyme catalyses the 
various protein cleavages observed in vivo. From this information potential 
therapeutic drugs may then be designed and synthesised to block the enzyme 
and hence stop the virus replicating, effectively "killing" it.
2.2 IDENTIFICATION OF THE ENZYME
Over recent years this enzyme has been the subject of extensive research by 
virtue of its novel catalytic mechanism and s t r u c t u r e . 4 3 , 4 4 , 6 8 - 7 0  Although it 
had been widely accepted that the L3 23 kDa viral polypeptide was the 
proteinase responsible for the viral polypeptide cleavages it was not until 
recently that this was c o n f i r m e d . 7 4 , 7 5  The L3 23 kDa polyprotein had been 
assumed to be the proteinase on the basis that a mutation of the virus, Ad tsl, 
displayed no p r o t e o l y s i s . 7 3 , 9 2  This mutation had been mapped to the gene 
coding for the L3 23 kDa protein i.e. when the gene does not make the protein 
no proteolysis is observed. In addition to this, all previous studies on the 
proteinase had been carried out using unfractionated cell extracts and without 
purification of the proteinase. This left the possibility, therefore, that although 
the L3 23 kDa protein was required for proteolysis it may not itself be the 
proteinase. Kemp and Webster demonstrated unequivocally that this was the 
proteinase by expressing the proteinase in E. coli, purifying to homogeneity 
and showing that it cleaved wild-type substrates.73 They further showed that 
the proteinase is active in its monomeric form. Underpinning this work was
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the discovery of a virally encoded protein fragment on which the proteinase is 
dependent for activity.71 Previously it had been demonstrated that pure 
proteinase was inactive whereas proteinase extracted from disrupted cells was 
active suggesting that a cofactor was required for activation. Following this 
Webster et a l, demonstrated that this cofactor was in fact a cleavage fragment 
of the viral polypeptide pVI.71 This cofactor is the 11 amino acid sequence 
from the C-terminus of pVI, denoted pVI-CT, and contains a cysteine residue 
essential for activation. Further they demonstrated that it is the oxidised 
disulphide linked dimer of this peptide which is the activating factor and not 
the reduced monomer. Thus Kemp et a l  were able to confirm that the L3 23 
kDa protein is the proteinase and that it is activated by a precursor protein 
cleavage fragment. This also explains the control mechanism of the proteinase, 
the virion polypeptides are synthesised late in infection and the cytopathic 
effect due to the action of the Ad 2 proteinase occurs late in infection. As has 
been demonstrated in other viral proteinase systems, notably the HIV-1 
proteinase, premature activation of the enzyme results in premature cleavage 
of precursor viral polypeptides which do not assemble coherently leading to 
premature cell death with a subsequent lack of efficient i n f e c t i v i t y . 7 9 , 8 0 , 9 3  
This disulphide linked dimer control mechanism represents a new type of 
activation mechanism suggesting a disulphide/-SH interchange between pVI- 
CT and thiols in the active site to expose the catalytic thiol and allow it, 
therefore, to adopt the proposed S‘/ImH+ catalytic system.
2.2.1 Modes of Inhibition
The four types of inhibition are, competitive, uncompetitive, noncompetitive 
and mixed inhibition.
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When an inhibitor molecule I binds reversibly to the active site of the enzyme 
and therefore prevents a substrate molecule A binding and when A binds to 
the active site preventing I binding then I acts as a competitive inhibitor, Le. I 
competes with A for a place in the active site.
i ^  E + PA + E
When an inhibitor molecule I binds reversibly to the enzyme-substrate, 
enzyme-intermediate or enzyme-product complex but not to the free enzyme 
then I acts as an uncompetitive inhibitor.
A + E ki
-^1
I
+
E.A
ki
E.A.I
E + P
When an inhibitor molecule I can bind reversibly to the free enzyme or the 
enzyme-substrate complex and when the dissociation constant of A from the 
enzyme-substrate complex is unaffected whether an inhibitor molecule is
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bound or not, then I acts as a noncompetitive inhibitor. This type of inhibition 
can occur when A and I bind simultaneously at different sites on the enzyme.
E + PE.AA + E
A.E.IA +E.I
When I acts as a mixed inhibitor it displays an inhibiton pattern which is a 
mixture between that for competitive and uncompetitive inhibition.
E + PE.AA + E ^
-iU
A.E.IA +E.I
2.3 DESIGN OF POTENTIAL INHIBITORS OF THE ENZYME
Before designing our inhibitors it was necessary to obtain an accurate picture 
of the active site, i.e. identify i) which cysteine residue is responsible for 
catalysis, ii) what other residues are involved and iii) what is their steric and 
electronic relationship to each other. Extensive site directed mutagenesis
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(SDM) experiments have been performed in order to i) show further that this 
is a cysteine proteinase and ii) identify which of the cysteines is the active site 
c y s t e i n e . 7 4 , 7 5  proteinase amino acid sequences from 12 adenovirus serotypes 
all display conserved residues at serine 95, serine 182, cysteine 104 and 
cysteine 122 and to a lesser extent serine 160 and cysteine 126/127 [See Figure 
4, Page 3 9 ].71 >75 jt had been proposed that serine 160, histidine 54 (the only 
conserved histidine) and aspartate 1 0 2  made up the catalytic triad, therefore, 
SDM experiments were performed in which all of the previously mentioned 
serine and cysteine residues were mutated, in turn, to a l a n i n e . 7 4 , 7 5  in addition 
the 2 conserved cysteines 104 and 122 were also changed to serines. The 
results clearly showed that mutations S95A, S182A and S I60A all resulted in 
active enzyme with little or no effect on relative activity. The mutations 
C l04A, C l22A and C104S and C122S resulted in a proteinase with less than 
5% of the wild-type activity. These results taken with the previous evidence 
confirmed that one of the conserved cysteines contributes the active site thiol. 
The absence of a thiol group at 104 or 122 interferes with the enzyme reaction 
mechanism either by preventing activation by the pVl-CT peptide or by 
abolishing the active site. Mutants containing C l26A, C l27A and the double 
mutant C126A/127A all resulted in active proteinase strongly suggesting that 
these semi-conserved residues do not contribute to the active centre or the 
activation mechanism. Attempts to determine which of the cysteine is the 
catalytic nucleophile and which is responsible for the disulphide activation 
were inconclusive although, interestingly Rancourt et al. observed an active 
proteinase with the mutation C122G.74 Activation and catalysis, therefore, 
appear to be inextricably linked. The fact that the proteinase partially digests 
pTP in the absence of pVl-CT and requires a 200 fold excess of pVI-CT for 
activation suggests that the activating peptide is not directly involved in the 
catalytic cycle. It is more likely, therefore, to contribute to setting up the 
appropriate redox state of one or more of the essential cysteine residues. The
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SDM experiments performed by Rancourt et a l using glycine agree in general 
with those of Webster et a l  using alanine, with the notable exception that 
C122G retains 81% activity.74 Activation by pVI-CT may promote a 
conformational change which in the C122G mutant is permitted by the small 
size of the glycine and hence some activity is observed. In addition, the mutant 
H54A resulted in an inactive proteinase supporting the proposal that H54 is 
required for catalysis.74 in niost cysteine proteinases the active site is 
composed of cysteine, histidine and aspartate although in papain only cysteine 
and histidine are directly involved. 83 Rancourt et a l failed to identify a third 
member for the active site, they also synthesised the serine mutant C104S and 
reported a 31% relative activity which further establishes a link with trypsin 
and poliovirus 3C proteinases which accept serine or cysteine as their active 
site nucleophiles.94 Their mutation C122S resulted in a complete loss of 
enzyme activity further supporting the proposal that C l04 is the active thiol.
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Figure 4: Alignment o f part o f the proteinase sequence showing the 3 
conserved cysteine residues. The figure shows residues 101-140 o f the Ad2 L3 
23 kDa protein aligned with the corresponding section o f the 23 kDa sequence 
from human serotypes 3, 4, 5, 12, 40 and 41, bovine serotypes 3 and 7 plus 
the murine and canine serotypes 1. The 3 conserved cysteines are highlighted.
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Determining the reaction mechanism of an enzyme is central to the design of 
specific inhibitors of that enzyme and although the Ad 2 proteinase has been 
classified as a cysteine proteinase its mode of action is still somewhat 
uncertain. Webster et a l  completed a comprehensive substrate specificity 
study which allows us to design potential inhibitor s. 70 The L3 23 kDa 
proteinase is remarkably substrate specific and obtaining a substrate specificity 
profile was essential to further investigate the catalytic mechanism. It was 
shown that a four amino acid motif to the carboxyl terminal of the scissile 
bond is the minimum requirement for c l e a v a g e . 7 0  The major requirements in 
the primary structure of this tetrapeptide are at which must be a glycine 
and at P4  which must be methionine, leucine or isoleucine. The restrictions on 
the types of scissile bonds cleaved P i—P ’l are somewhat less. Providing 
glycine occupies P'l almost any amino acid may occupy Pi and be cleaved, 
except possibly proline. This was supported by molecular modelling which 
showed that the side chains of residues at Pi point away from the intolerant 
sites of P2 and P4 .7 0  if  any other amino acid occupies P'l then there are 
increased steric restrictions on Pi, indeed, in the natural substrates where 
glycine is not at the P'l position then in almost all cases glycine occupies the 
Pi position. From these data two profiles may be drawn;
(M,L,I) X G O iX  and (M,L,I) X G X iG
Using these profiles Webster et a l confirmed all known cleavages in the viral 
substrates and predicted unidentified cleavage sites in known substrates pVI, 
pVII, pVIII, pTP, Ilia as well as the penton, hexon, 52 kDa, early 21 kDa, 
145 kDa and D172 proteins. This group has designed and tested a range of 
potential inhibitors based on the four amino acid motif in an attempt to further 
understand the catalytic mechanism of this enzyme [See Figure 5, Page 41].76 
The tetrapeptide derivatives were of the form;
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R-LAG-(NH2 -CH2 )-R'
where R is the nitrogen protecting group Cbz or t-Boc and R' represents the 
downstream residue over the scissile bond. Various derivatives were 
synthesised as R'; ester, acid, amide, nitrile and dimethylacetal.
R
Me
Me
oco-
Me
Q p o o o - X
F3CCO-
H-
-COgH
"COgMe
-COgEt
-COgtBu
-CONHg
-CONHMe
“CONMeg
-CONMeEt
-CON(OMe)Me
-CH(OMe)g
-CN
Figure 5; Potential inhibitors synthesised and tested by our group.
All the esters were substrates including the tertiary butyl ester, this was the 
only ester with a t-Boc N-protection and acted as a substrate at two sites. The 
fact that this enzyme hydrolyses t-butyl esters in itself is interesting since the 
usual manner in which these sterically hindered esters are hydrolysed is under 
acidic conditions. It was observed that a valine residue at P'l resulted in very 
slow cleavage and it was postulated that there is some form of tertiary 
structure in vivo which pulls the hydrophobic residue away from the scissile 
bond and allows efficient cleavage. The hydrolysis of the t-butyl ester may 
well be similar in that it seems probable that some hydrophobic interaction is 
set up which pulls or pushes the bulky group away from the carbonyl which
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facilitates nucleophilic attack by the sulphur ion. The acids and amides did not 
act as inhibitors at all and were not pursued. The dimethylacetals and nitriles 
acted as moderate and good inhibitors respectively. The reciprocal plots of 
rate versus inhibitor concentration for the dimethylacetals indicated that more 
than one molecule of inhibitor can bind to the enzyme. The double reciprocal 
plots of initial rate versus substrate concentration were linear and intersected 
such that the apparent was not affected Le. acetal acts as a noncompetitive
inhibitor. The nitrile derivatives all performed as good inhibitors and also 
acted noncompetitively [See Scheme 5, Page 42].
;
Scheme 5: The nitrile as a reversible inhibitor and possible thioimidate 
adduct formation.
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It is interesting that these compounds act as noncompetitive inhibitors since 
they closely resemble the wild-type P4 -P 1 motif and would therefore be 
expected to act as competitive inhibitors. However, if one considers the order 
in which events take place at the active site and assume that after cleavage the 
N-terminal product is released first then another inhibitor molecule may enter 
and trap the C-terminal product on the enzyme. Coupled with its ability to 
bind to the same region in the absence of the C-terminal product then the 
inhibitor would act in a noncompetitive manner and be best described as a 
product analogue. If the C-terminal product desorbs first then the remaining 
N-terminal fragment would block the P4 -P 1 subsites against another inhibitor 
molecule entering. Therefore it seems probable that in contrast to many 
cysteine proteinases, including papain, this enzyme releases the N-terminal 
product first [See Scheme 6 , Page 44]. All the compounds were expected to 
bind, the fact that they did not and that those that did all possess a form of 
"good leaving group" suggests a covalently bonded intermediate.
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Schem e 6 : Alternative hydrolysis mechanism o f the Ad L3 23 kDa 
proteinase.
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This is in accord with similar observations in other cysteine proteinases, the 
nitrile Ac-Phe-NHCH2CN inhibits papain forming a thioimidate adduct.95 
Obviously the chemical mechanism of this enzyme is not simple, one of the 
problems faced when studying the kinetics of such a system is that the assay 
systems are not continuous and therefore depend on removing aliquots at 
specific time intervals from the reaction mixture and analysing them 
separately. These systems are inherently subject to large degrees of 
experimental error. A continuous assay system abolishes these errors where a 
reaction mixture is analysed in situ without the need to remove aliquots.
An additional objective of our work was the development of a UV continuous 
assay system using the chromophore /^-nitroaniline. However, the first step 
was to synthesise the ester analogues of the p-nitroanilides and to use them as 
inhibitor probes to assess whether or not these types of compounds will be 
turned-over or not. In these systems where R'= p-nitroaniline, appearance of 
p-nitroaniline, the cleavage product, is monitored, hence initial rates, Vmax's 
and Km’s may be determined directly. Compounds synthesised and tested were 
of the form;
R-LAXG-R*
where R= Cbz; X= G, (25)-A, (2R)-A, (25)-V; R'= OPri, p-nitroaniline.
2.4 SOLUTION PHASE PEPTIDE SYNTHESIS
There are numerous methods for synthesising peptides in the solution phase, 
including the use of acid chlorides or carbodiimides for peptide couplings.
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We synthesised peptide fragments and final peptides using the mixed 
anhydride method of peptide coupling.^^ This method was chosen for its 
advantages in reaction time, yield, ease of purification and quality of the 
products. The mixed anhydride method has been studied in detail to increase 
yield and minimise the possibility of racémisation. The reaction uses alkyl 
chloroformâtes as peptide forming reagents. A suitably protected amino acid 
reacts with the alkyl chloroformate in the presence of a base, to form an 
anhydride. A second suitably protected amino acid is then added to the 
reaction mixture which then reacts with the anhydride to form the peptide 
linkage [See Scheme 7, Page 46].
a
MeÔ R'. Hor» bO'
1 " :k "
o
H R"
Scheme 7: Reaction mechanism o f the mixed anhydride peptide coupling.
It is believed that the first step of the reaction is the attack of the tertiary base 
on the alkyl chloroformate to form a quaternary intermediate which in turn 
reacts with the carboxylic acid. An important consideration is that of
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racémisation, which can be minimised depending on the steric bulk of the base 
and the choice of solvent. It has been found that methylamine reacts the fastest, 
but results in extensive racémisation. Base, solvent, temperature and alkyl 
chloroformate variations have been examined, it was found that the best 
results were obtained using a combination of N-methylmorpholine (NMM), 
isobutylchloroformate and dry tetrahydrofuran (THF). This combination of 
reagents was used in the course of this work. However, when there was a 
problem of solubility of one or more of the starting materials, a minimum 
volume of dry dimethylformamide (DMF) in THF was used to aid the 
solubility of the reactants.
2.5 SYNTHESIS OF THE TETRAPEPTIDE ESTERS
We chose to synthesise these compounds from the two appropriately protected 
dipeptides which would be prepared from the monoprotected amino acids. 
This method was chosen rather than the sequential adding of residues as 
dipeptides tend to be easier to handle in terms of recrystallisation, 
chromatography and solubility. Also the yield from coupling two dipeptides is 
significantly higher than that of coupling a tripeptide and a monprotected 
amino acid. This approach gave us the common dipeptide precursor on the N- 
terminus; Cbz-Leu-Ala-OH, to which we coupled the varying other half; NH- 
X-Gly-Pri, to give the tetrapeptides desired.
2.5.1 Synthesis of the Dipeptide Precursor Cbz-Leu-Ala-OH (4)
Carboxybenzyl (Cbz) protection of (25)-leucine was achieved using benzyl 
chloroformate and aqueous sodium hydroxide under Schotten-Baumann^V 
conditions to give Cbz-(25)-leucine (1) in 96% yield {Dmax 1720 cm~l 
urethane CO}. MethyI-(25')-alaninate hydrochloride (2) was prepared from
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(25)-alanine, thionyl chloride and methanol in 62% yield {m.p. 110-2 °C 
(lit.98, 109-110 °C)}. The two monoprotected amino acids (1) and (2) were 
coupled using mixed anhydride methodology to give methyl carboxybenzyl- 
(25)-leucyl-(25)-alaninate (3) in 77% yield after recrystallisation from ethyl 
acetate/ light petroleum {m.p. 91-2 °C (lit.99, 92-3 °C)}. Treatment of the 
dipeptide (3) with 1 mol dm~3 sodium hydroxide at 35 °C for 3 h, followed 
by acidification gave carboxybenzyl-(2S)-leucyl-(25')~alanine (4) in 80% yield 
(m.p. 149-150 (lit. 100, 150-1 °C)} [See Scheme 8 , Page 48].
OCHaOH
O '( X
OH
R e a g e n ts  a n d  c o n d i t i o n s :  (i) THF, DMF, NMM, isobutyi chloroformate, -10°C, 1 h, 77%; 
(ii) MeOH, NaOH, 2 h, 80%.
Scheme 8 : Synthesis o f dipeptide precursor (4).
2.5.2 Synthesis of the Various Carboxyl Terminal Dipeptides H-X- 
Gly-OPri
Carboxybenzyl (Cbz) protection of glycine was achieved in a manner identical 
to (1) to give carboxybenzyl glycine (5) in 55% yield {m.p. 119 °C, lit.lOl, 
120 °C}. Isopropyl glycinate hydrochloride (6 ) was prepared in a manner 
identical to (2) in 8 6 % yield {m.p. 95-7 °C, lit. 1 0 2  ^ 96 °C}. The two
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monoprotected amino acids (5) and (6 ) were coupled using mixed anhydride 
methodology in a manner identical to that for (3) to give isopropyl 
carboxybenzyl glycyl glycinate (7) in 74% yield {m.p. 92-4 °C}. Removal of 
the nitrogen protecting group from the dipeptide (7) was effected by catalytic 
hydrogenolysis (H2 , Pd/C) over 2 h, followed by removal of the by-products 
under reduced pressure to give isopropyl glycyl glycinate (8 ) in 71% yield 
{m.p. 120 °C (decomp.)}. 103 Two further dipeptides, isopropyl-(25')-alanyl 
glycinate and isopropyl-(2 R)-alanyl glycinate, were synthesised in a manner 
identical to that for (8 ) starting with carboxybenzyl-(25')-alanine and 
carboxybenzyl-(2R)-alanine respectively.
2.5.3 Coupling of the Dipeptide Fragments
The three tetrapeptide esters; isopropyl carboxybenzyl-(25)-leucyl-(25)-alanyl 
glycyl glycinate (9), isopropyl carboxybenzyl-(25')-leucyl-(25)-alanyl-(25')- 
alanyl glycinate (1 0 ) and isopropyl carboxybenzyl-(25')-leucyl-(25')-alanyl- 
(2R)-alanyl glycinate (11) were all prepared in the same manner. Isopropyl 
carboxybenzyl-(25')-leucyl-(25)-alanyl glycyl glycinate (9) was prepared by 
the coupling of (4) and (8 ) using mixed anyhdride methodology in 65% yield 
after recrystallisation from methanol {Found: C, 58.75; H, 7.6; N, 11.45. 
Calc, for C24H36N4 O7 : C, 58.5; H, 7.4; N, 11.4%}. Isopropyl carboxybenzyl-
(25')-leucyl-(2S)-alanyl-(2S)-alanyl glycinate (10) was prepared in the same 
manner from (4) and isopropyl-(25)-alanyl glycinate in 74% yield after 
recrystallisation from methanol/ water {Found: C, 59.1; H, 7.55; N, 10.85. 
Calc, for C25H38N4 O7 : C, 59.25; H, 7.55; N, 11.05%}. The {2R) analogue of
(10), isopropyl carboxybenzyl-(25)-leucyl-(25)-alanyl-(2R)-alanyl glycinate
(11) was prepared from (4) and isopropyl-(2 R)-alanyl glycinate in 46% yield 
after recrystallisation from methanol/ water {Found: C, 59.25; H, 7.45; N,
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10.75. Calc for C25H38N4 O7 : C, 59.25; H, 7.55; N, 11.05%} [See Scheme 9, 
Page 50].
cr I- *
(5)
H3N 
Cl- O
(6)
(9)
(7)
(8)
R = (5 )M e, (R) M e,H
R e a g e n t s  a n d  c o n d i t i o n s  :(i) THF, DMF, NMM, isobutyl chloroformate, -10°C, 1 h, 74%;
(ii) MeOH, C/Pd 10%, Hz (g), 2 h, 71%;
(iii) (4), THF, DMF, NMM, isobutyl chloroformate, -10°C, 2 h, 65%.
Scheme 9: Synthesis o f tetrapeptide esters.
2.6 SYNTHESIS OF THE TETRAPEPTIDE p-NITRGANILIDES
The synthesis of this series of compounds was simplified considerably by 
building the tetrapeptides sequentially. This was because of the reactivity of 
the p-nitroanilide group which is both acid and base labile. Glycine-/?- 
nitroanilide was, therefore, coupled to a series of tripeptide free acids. The 
common precursor to all the tripeptides was the dipeptide Cbz-Leu-Ala-OH 
(4) and, as for the tetrapeptide esters, the residues which varied at ? 2  where 
Gly, (25)-Ala and (2R)-Ala. The attempted synthesis of the (25)-Val analogue 
was not successful. It was hoped that using these compounds we could have 
developed a continuous UV assay system for this enzyme using the p- 
nitroaniline chromophore.
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2.6.1 Synthesis of the Tripeptide Cores
The three tripeptides; carboxybenzyl-(25)-leucyl-(25)-alanyl glycine (13), 
carboxybenzyl-(25)-leucyl-(25)-alanyl-(25)-alanine (15) and carboxybenzyl- 
(25)-leucyl-(25)-alanyl-(2R)-alanine (17), were all prepared in the same 
manner as (3) [See Figure 6 , Page 52]. The two monoprotected species (4) 
and (6 ) were coupled using mixed anhydride methodology to give isopropyl 
carboxybenzyl-(25)-leucyl-(25)-alanyl glycinate (12) in 55% yield after 
purification by silica chromatography {m.p. 137 °C}. Treatment of (12) with 
1 mol dm-3 sodium hydroxide at 35 °C for 2 h, followed by acidification gave 
carboxybenzyl-(25)-leucyl-(25)-alanyl glycine (13) in 83% yield {m.p. 149 
°C}. Methyl carboxybenzyl-(25)-leucyl-(25)-alanyl-(25)-alaninate (14) was 
prepared in a manner identical to (12) from (4) and (2) in 6 8 % yield after 
purification by silica chromatography {m.p. 174-6 °C}. Treatment of (14) 
with 1 mol dm-3 sodium hydroxide at 35 °C for 2 h, followed by acidification 
gave carboxybenzyl-(25)-leucyl-(25)-alanyl-(25)-alanine (15) in 85% yield 
{m.p. 183-4 °C}. Methyl carboxybenzyl-(25)-leucyl-(25)-alanyl-(2/?)- 
alaninate (16) was prepared as for (12) from (4) and methyl- (2 R)-alaninate 
hydrochloride in 6 6 % yield after purification by silica chromatography {m.p. 
164 °C}. Carboxybenzyl-(25)-leucyl-(25)-alanyl-(2R)-alanine (17) was 
prepared in a manner identical to that for (13) in 54% yield {m.p. 170 °C). 
A further tripeptide synthesised was methyl carboxybenzyl-(25)-leucyl- (25) - 
alany 1- (25)-valinate (18) in the same manner as (12) but the base hydrolysis 
of the methyl ester was unsuccessful using a variety of sodium hydroxide 
concentrations, molar ratios and reaction temperatures, so this derivative was 
not pursued.
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Figure 6 : The three tripeptide cores (13), (15) and (17).
2.6.2 Synthesis of the Tetrapeptide p-Nitroanilide Derivatives
Carboxybenzyl-(25')-leucyl-(25')-alanyl glycyl glycine-p-nitroanilide (19) was 
prepared from (13) and glycine-p-nitroanilide using mixed anhydride 
methodology. Although the Ôh NMR showed that reaction had occured {Ô 
7.83 (2H, d, p-nitroanilide protons 2 & 6) and Ô 8.22 (2H, d, p-nitroanilide 
protons 3 & 5)}, the yield of the reaction was very low (16%). 
Carboxybenzyl-(25)-leucyl-(25')-alanyl-(2/?)-alanyl glycine-p-nitroanilide 
(20) was prepared in a manner identical to that for (19) from (17) and 
glycine-p-nitroanilide in a moderate yield of 42% (Found: C, 57.2; H, 6.1; N, 
14.05. Calc for C28H36N6O8 : C, 57.55; H, 6.2; N, 14.35%) [See Scheme 10,
Page 53]. Due to the lack of time the synthesis of the other tetrapeptide p- 
nitroanilides, carboxybenzyl-(25)-leucyl-(2S)-alanyl-(25)-alanyl glycine-p-
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nitroanilide and carboxybenzyl-(2S)-leucyl-(25')-alanyl-(25)-valyl glycine-p- 
nitroanilide, was not completed.
(4) o . R'
ci-
(6) (12)
OH HaN-^
NOo
(13)
NO,
(19)
R = ( 2 S ) M e ,( 2 f î )  Me, H
R eagents and conditions; (i) THF, DMF, NMM, isobutylchioroformate, -10  °C, 1 h, 55%;
(ii) MeOH, NaOH, 2 h, 83%;
(iii) THF, DMF, NMM, isobutyichioroformate, -10  °C, 2 h, 16%.
Scheme 10: Synthetic route to the tetrapeptide p~nitroanilides
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2.6.3 Proposed Synthetic Route to Glycine-p-Nitroanilide
The synthetic problem associated with amino acid p-nitroanilide derivatives is 
the electron deficient amide that is susceptible to nucleophilic attack on the 
carbonyl. During a standard synthesis of peptides which involves protections 
using aqueous base, deprotections using aqueous base and couplings which 
involve three separate nucleophilic attacks on electron deficient carbonyls it is 
impossible that this labile group should not be hydrolysed. Glycine-p- 
nitroanilide is a relatively expensive compound to buy, p -n itroan iline, 
however, is not and the possibility of synthesisng glycine-p-nitroanilide was 
investigated.
A literature method for the deprotection of N-^Boc groups which does not 
require the relatively harsh conditions of aqueous base such as sodium 
hydroxide, but uses trimethyl silyl iodide would be a possible s o l u t i o n .  1 0 4 ,1 0 5  
According to the literature this method proceeds under very mild conditions 
with very high yields and, in the example quoted iBoc-Gly-OBzl, the reaction 
is completed within 20 min without hydrolysing the e s t e r .  105 This appeared to 
be an attractive alternative and was, therefore, pursued further.
iButoxycarbonyl glycine was prepared from di-ibutyldicarbonate, glycine and 
aqueous sodium hydroxide in 1,4 dioxane in good yield and reacted with p- 
nitroaniline again using mixed anhydride methodology. This method was 
chosen for its simplicity and speed of reaction although the aromatic amine is 
not a good nucleophile and an extra equivalent of NMM was added to assist in 
the removal of the amine proton. The reaction went with moderate yield and 
the product was purified by recrystallisation from methanol and carried on to 
the next step. The literature method was followed for the removal of the 
tertiary butoxycarbonyl group [See Scheme 11, Page 55].105 There was no
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evidence in the IH NMR that reaction had occured and following several 
further unsuccessful attempts this synthetic route was abandoned. It is unclear 
why this was not successful.
OH (i)
O
O
° o
OH + HgN-^x /
(ii)
o
R eagents and conditions: (i) 1,4 dioxan, NaOH, (OH 3 )3 0 0 0 0  2000(O H  3)3;
(ii) THF, DMF, NMM, isobutylchloroformate, -10 °0
(iii) (OH 3)3SiSi(Ohfe)3, 12. CH 3ON, 40 °0 .
NO,
NO2
Scheme 11: Synthetic strategy towards glycine-p-nitroanilide
2.7 BIOLOGICAL TESTING OF THE TETRAPEPTIDE ESTERS
The series of three tetrapeptide esters were tested in an enzyme assay as 
potential inhibitors. The fact that the enzyme cleaves esters as substrates was 
also established by ourselves during the design and synthesis of potential 
inhibitors. To date the esters tested were of the form Cbz-Leu-Ala-Gly-Gly- 
OR, where R= Me, Et, tBu.^^ The compounds in our study are all isopropyl 
esters and the amino acid sequence has been varied at ? 2 . Kemp et a i reported 
that they observed no cleavage of synthetic viral peptides when the residue at 
? 2  was (25")-alanine or larger and there seems to be a very strict steric 
specificity at this r e s i d u e . 7 0  We have, therefore, synthesised the "wild-type"
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LAGG, LA-(25)-AG and LA-(2/?)-AG ester derivatives in order to probe the 
steric properties around this P2 site since it may be that there is a gap on the 
other side to the (25)- stereochemistry and that the (2/?)-alanine derivative 
may be turned over.
2.7.1 Peptide Assay for Recombinant Adenovirus 2 L3 23kDa 
Enzyme
The assay used is a modification of the one developed by Kemp et a l  during 
their work to identify all of the viral peptide cleavage sites confirming their 
work on substrate specificity [See Appendix 1, Page 9 2 ].69,70
2.7.2 Results
Cbz-(25)-Leu-(25)-Ala-Gly-Gly-OPri (9);
(9) was assayed at concentrations of 0.006 mM and 0.031 mM in DMSO and 
at both concentrations there was no observable inhibition of the proteinase. 
We would not expect this compound to inhibit since it is based on the 
tetrapeptide motif and therefore mimics the "wild-type" peptide substrates. 
Indeed know that wild-type esters are substrates.^6
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Cbz-(25)-Leu-(25)-Ala-(25)-Ala-Gly-OPri(10):
This tetrapeptide differs from the "wild-type" at P2 The glycine residue has 
been replaced by (25)-alanine, as reported by Kemp et al. this is not a natural 
substrate and does not fit their motif.70 A factor which was detrimental to the 
testing of this compound was the fact that it required a fairly high 
concentration of methanol to dissolve the peptide (7.7% MeOH in the assay).
(10) was assayed at concentrations of 0.15 mM and 0.77 mM. At the lower 
concentration of 0.15 mM no inhibition was observed. At the higher 
concentration of 0.77%, inhibition of 37.41% was observed even after the 
inhibition due to the high methanol concentration had been taken into 
consideration (2 0 % inhibition of initial rate due to a methanol concentration 
of 7.7% in the assay). This is very poor and (10) is certainly not a potent 
inhibitor, the estimated Ki for this inhibition is 2.1 mM.
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Cbz-(2S)-Leu-(25)-Ala-(2/?)-Ala-Gly-OPri(ll):
(11) was also assayed at concentrations of 0.15 mM and 0.77 mM and with 
the same high concentration of methanol (7.7% in the assay and 20% 
inhibition of the initial rate). As for (10), (11) showed no inhibition at the 
lower concentration. At the higher concentration (11) showed 14.64% 
inhibition and the estimated Ki was 5.3 mM, this is considerably lower than 
for (10) and again (11) is not a potent inhibitor. The lower percentage 
inhibition and higher estimated Ki may be indicative that this (2/?)-A la 
analogue has lessened the steric restriction around the P2 subsite and 
therefore, appears more like the "wild-type" substrates. Kemp et a l  showed, 
using molecular modelling of proposed and actual cleavage sites in the viral 
polypeptide precursors, that only sequences that i) hold the sidechain of the 
residue at P'l away from the scissile bond are cleaved and ii) that even the 
sidechain of alanine at P2 protrudes enough in terms of the secondary 
structure to prevent access to the proteinase.70 This tends to indicate that, 
whilst the {2R) analogue has indeed lessened the steric restriction slightly, 
these steric restrictions are much more severe that at first presumed and 
indeed "claustrophobic" particularly around the P2-S2 site.
See Experimental, page 80 and Appendix One, page 92, for full assay details 
and results.
CHAPTER THREE
EXPERIMENTAL PROCEDURE
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3.0 EXPERIMENTAL PROCEDURE
Elemental microanalyses were performed in the departmental microanalytical 
laboratory.
NMR spectra were recorded on a Bruker AM-300 (300 MHz; f.t. iR-NM R, 
and 74.76 MHz; l^C-NMR), or a Varian gemini 200 (200 MHz; f.t. IH-NMR 
and 50.31 MHz; i^C-NMR) spectrometers. IH-NMR spectra are described in 
parts per million downfield shift from TMS and are reported consecutively as 
position (Ôh  or Ôc), relative integral, multiplicity (s -singlet, d -doublet, t
-triplet, q -quartet, dd -double of doublets, sep -septet, m -multiplet, and br 
-broad), coupling constant (Hz) and assignment (numbering according to the 
lUPAC nomenclature for the compound). iH-NMR were referenced internally 
on 2hOH (4.68 ppm), CHCI3 (7.27 ppm) or DMSO (2.47 ppm). l^C-NMR 
were referenced on CH3OH (49.9 ppm), C2HCI3 (77.5 ppm), or DMSO (39.70 
ppm).
IR spectra were recorded on a Perkin-Elmer 1710 f.t. IR spectrometer. The 
samples were prepared as Nujol mulls, solutions in chloroform or thin films 
between sodium chloride discs. The frequencies (o) as absorption maxima are 
given in wavenumbers (cm-1) relative to a polystyrene standard. Mass spectra 
and accurate mass measurements were recorded on a VG 70-250 SE, a Kratos 
MS-50 or by the SERC service at Swansea using a VG AZB-E. Fast atom 
bombardment spectra were recorded using glycerol as a matrix. Major 
fragments were given as percentages of the base peak intensity (100%). UV 
spectra were recorded on Pye-Unicam SP8-500 or SP8-100 spectro­
photometers.
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Flash chromatography was performed according to the method of Still et 
(Z/.106 using Sorbsil C 60 (40-60 \im  mesh) silica gel. Analytical thin layer 
chromatography was carried out on 0.25 mm precoated silica gel plates 
(Macherey-Nagel SIL g/UV254) and compounds were visualised using UV 
fluorescence, iodine vapour, ethanolic phosphomolybdic acid, or ninhydrin.
Melting points were taken on an Electrothermal melting point apparatus and 
are uncorrected. Optical measurements were measured at 23 °C on a Optical 
Activity AA-1000 polarimeter using 10 or 20 cm path length cells; [a]o values 
are given in 1()-1 deg cm^ g-1.
The solvents used were either distilled or of analar quality and light petrol 
ether refers to that portion boiling between 40 and 60 °C. Solvents were dried 
according to literature procedures. Ethanol and methanol were dried using 
magnesium turnings. Isopropanol, isopentanol, DMF, toluene, CH2CI2 ,
acetonitrile, diisopropylamine, triethylamine and pyridine were distilled over 
CaH 2 . THF and diethyl ether were dried over sodium/ benzophenone and
distilled under nitrogen. Thionyl chloride was distilled over sulphur, and the 
initial fractions were always discarded. BuLi was titrated according to the 
method of Lipton.107
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Carboxybenzyl-(2S)-leucm e (1)
OH
To a vigorously stirred solution of (25)-leucine (3.03 g, 23 mmol) in water 
(80 cm^) containing sodium hydroxide (3.2 g, 80 mmol) was added benzyl 
chloroformate (5.4 cm^, 37 mmol) in 5 portions over 15 min. The reaction 
mixture was stirred for 3 h at 0 °C and then extracted with diethyl ether (2 x 
50 cm3). The aqueous phase was acidified with concentrated hydrochloric acid 
and extracted with diethyl ether (3 x 50 cm^). The ethereal extracts were 
washed with brine (50 cm^), dried (Na2S0 4 ) and concentrated under reduced 
pressure to give (1) as a thick yellow oil (5.8 g, 96%), 'O^ax (thin film)/cm-l
3320 (NH), 3090-3040 (aromatic), 2960-2290 (aliphatic), 1720 (urethane CO) 
and 1710 (acid CO); ôy (200 MHz; C^HClg) 0.97 (6 H, d, CH(CH3)2 ), 1.52- 
1.79 (3H, m, CH2CH(CH3)2), 4.38 (IH, t, CHCO2 H), 5.11 (2H, s, C6H5CH2) 
5.29 (IH, d, NH), 7.36 (5H, m, CgHg) and 9.5 (IH, br, CO2H); ôc (50.3 MHz; 
C 2 H C I3 ) 22.20 & 23.34 (C H (C H 3 )2 ), 25.25 (C H (C H 3 )2 ), 41.94 
(CH2CH(CH3)2 ), 52.88 (CHCO2H), 67.69 (C6H5CH2 ), 128.62, 128.74 &
129.04 (aromatic), 136.59 (quat. aromatic), 156.71 (urethane CO) and 178.71 
(CO2H).
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M ethyl-(2S)-alaninate hydrochloride (2)
OCH
To a stirred suspension of (25')-alanine (6.02 g, 67.6 mmol) in dry methanol 
(50 cm3) at 0 °C was added thionyl chloride (13 cm^, 178.2 mmol) dropwise 
with vigorous stirring. The reaction mixture was then refluxed for 2 h. The 
solution was allowed to cool and the methanol removed under reduced 
pressure to give a white solid which was recrystallised from dichloromethane/ 
diethyl ether to give the ester (2) as white crystals (5.80 g, 62%), m.p. 110-1 
°C (lit.98, 109-110 °C); Umax (Nujol)Zcm-l 3430 (NH) and 1740 (ester CO); 
ÔH (200 MHz; ^ O )  1.53 (3H, d, CHg), 3.74 (3H, s, OCH3) and 4.10 (IH, q, 
CH); ÔC (50.3 MHz; 2H2O) 17.95 (CH3), 51.84 (CH), 56.43 (CO2ÇH 3) and 
174.13 (CO2 CH3 ).
Methyl carboxybenzyl-(2S)-leueyl-(2S)-alanmate (3)
Carboxybenzy 1-(25")-leucine (1) (1.15 g, 4.35 mmol) was dissolved in dry 
THF (50 cm3) with stirring at -15 °C. N-Methyl Morpholine (NMM) (0.48 
cm5, 4.35 mmol) was added and the mixture was then allowed to stir for 10
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min. Isobutyl chloroformate (0.57 cm^, 4.35 mmol) was added and a white 
precipitate of NMM hydrochloride was formed. Meanwhile, methyl-(25")- 
alaninate hydrochloride (2) (0.613 g, 4.39 mmol) was dissolved in dry DMF 
(10 cm3) and NMM (0.48 cm^, 4.35 mmol) was added. This mixture was 
added to the THF mixture shortly after the addition of isobutyl chloroformate 
at -15 °C. The THF/DMF reaction mixture was maintained at -15 °C for 15 
min and allowed to warm to room temperature. After 1 h the NMM 
hydrochloride was filtered and the solvents removed under reduced pressure 
to leave a thick yellow oil. The oil was dissolved in dichloromethane (50 cm^) 
and washed successively with 10% citric acid (50 cm^), 5% NaHCOg (50 cm^) 
and saturated brine (50 cm^), dried (MgSO/^) and the solvent removed under 
reduced pressure to give an off white solid which was recrystallised from 
ethyl acetate/ light petrol to give (3) as a white solid (1.03 g, 77%), m.p. 91-2 
°C (lit.99, 92-3 °C); u^ax (Nujol)/cm“l 3300 (NH), 1740 (ester CO), 1690 
(urethane CO) and 1650 (amide CO); Ôh (200 MHz; C^HClg) 0.94 (6 H, d, 
CH(CH3)2), 1.39 (3H, d, CHCH3), 1.47-1.77 (3H, m, CH2CH(CH3)2 ), 3.75 
(3H, s, OCH3), 4.20 (IH, m, NHCHCH2 ), 4.56 (IH, m, NHCHCH3), 5.11 (2H, 
s, C6H5CH2 ), 5,26 (IH, d, NHCHCH2-), 6.58 (IH, d, NHCHCH3) and 7.35 
(5H, m, C6H5-); ÔC (50.3 MHz; C2HCI3) 18.56 ((NHCHCH3), 22.47 & 23.41 
(CH(CH3)2 ), 25.07 (CH(CH3 )2 ), 42.10 (CH2CH(CH3 )2 ), 48.48 (ÇHCH3 ), 
52.94 (CHCH2CH(CH3)2), 53.84 (OCH3), 67.49 (C6H5CH2), 128.51, 128.67
& 129.01 (aromatic), 136.71 (quat. aromatic), 156.77 (urethane CO), 172.54 
(NHCO) and 173.71 (ÇOCH3).
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C arboxybenzyl-(25)-leucyl-(25)-alanine (4)
To a stirred solution of methyl carboxybenzyl-(25')-leucyl-(25')>alaninate (3) 
(0.53 g, 1.50 mmol) in methanol (20 cm^) was added 1 mol dm-3 aqueous 
NaOH (1.9 cm3, 1.8 mmol). The reaction mixture was allowed to stir at room 
temperature, and the reaction followed to completion by tic. Methanol was 
removed under reduced pressure after 2  h, and the remaining aqueous layer 
neutralised and acidified to pH 2 with 1 mol dm-^ HCl. The resultant white 
precipitate was filtered, dried (MgS0 4 ), recrystallised from dichloromethane/
light petrol and dried to give pure (4) as a white solid (0.41 g, 80%), m.p. 
149-150 °C (lit. 100 , 150-1 °C); (Nujol)/cm-l 3290 (NH), 3280 (NH), 
1720 (acid CO), 1710 (urethane CO) and 1700 (amide CO); ôy (200 MHz; 
C2HC13) 0.92 (6 H, d, CH(CH3)2), 1.40 (3H, d, CHCH3), 1.55-1.67 (3H, m, 
CHCH2CH(CH3)2), 4.31 (IH, q, NHCHCH2), 4.54 (IH, m, NHCHCH3), 5.10 
(2H, s, C6H5CH2 ), 5.70 (IH, d, urethane NH), 7.06 (IH, d, amide NH) and 
7.33 (5H, s, aromatic CH); 5c (50.3 MHz; C2HCI3) 18.36 (CHCH3), 22.47 & 
23.39 (CH(CH3 )2 ), 25.06 (C H (C H 3 )2 ), 41.80 (CH 2 C H (C H 3 )2 ), 48.68 
(CHCH3), 53.85 (CHCH2CH(CH3)2 ), 67.72 (C6H5CH2 ), 128.51, 128.75 &
129.04 (aromatic CH), 136.51 (quat. aromatic) 157.01 (CO2NH), 173.14 
(CONH) and 176.15 (CO2H).
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Carboxybenzyl glycine (5)
This compound was prepared in a manner identical to that for (1) using 
glycine (3 .0 2  g, 40 mmol) to give a white solid which was recrystallised from 
ethyl acetate/ light petrol to give (5) as white crystals (4.67 g, 55%), m.p. 
118-119 °C (lit. 101, 120 °C); D^ax (Nujol)/cm-l 3330 (NH), 3030 (OH), 2580 
(aromatic CH), 1720 (urethane) and 1685 (acid); Ôh (200 MHz; de-T>MSO) 
3.69 (2H, d, NHCH2), 5.06 (2H, s, C6H5CH2), 7.38 (5H, m, aromatic CH) and 
7.61 (IH, t, NH); ôc (50.3 MHz; 2H2O) 42.40 (NHCH2), 65.73 (C6H5ÇH2 ),
128.01, 128.10 & 128.64 (aromatic CH), 137.28 (quat. aromatic), 156.78 
(CONH) and 171.88 (CO2 H).
Isopropyl glycinate hydrochloride (6 )
To a stirred suspension of glycine (10.03 g, 0.134 mol) in dry isopropanol 
(150 cm3) at 0 °C was added thionyl chloride (26 cm^, 0.256 mol) dropwise 
with vigorous stirring. The reaction mixture and was then refluxed for 2 h, 
the solution allowed to cool and the isopropanol removed under reduced 
pressure to give a white solid which was recrystallised from isopropanol/
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diethyl ether to give (6 ) as white crystals (17.63 g, 8 6 %), m.p. 85 °C (lit.l0 2  ^
84-6 °C); 5h (200 MHz; rfe-DMSO) 1.25 (6 H, d, CH(CH3)2 ), 3.71 (2H, s, 
CH2CO), 5.0 (IH, sep, CH(CH3)2) and 8.65 (3H, s, NH3CI); 5c (50.3 MHz; 
^6-DMSO) 21.74 (CH(£H3)2), 39.85 (ÇH2CO), 69.65 (CH(CH3)2) and 167.29 
(CO).
Isopropyl carboxybenzyl glycyl glycinate (7)
°  a n
This compound was prepared in a manner identical to that for (3), using (5) 
(2.00 g, 9.57 mmol) and (6 ) (1.47 g, 9.57 mmol). The crude dipeptide was 
purified by trituration with diethyl ether to give pure dipeptide (7) as a white 
solid (2.18 g, 74%), m.p. 92-4 °C; m /z (Found; [M + H]+, 309.1450. 
C 1 5H2 1 N 2 O5 requires 309.1372); 5h  (200 MHz; C2 HCI3 ) 1.25 (6 H, d, 
CH(CH3)2), 3.89 (2 H, d, NHCH2CO2), 3.95 (2H, d, NHCH2CO), 5.04 (IH, 
sep, 0 CH(CH3)2), 5.13 (2H, s, C6H5CH2), 5.61 (IH, t, CONH), 6 .6 8  (IH, t, 
NHCH2) and 7.36 (5H, s, CgH^); 6 c  (50.3 MHz; C2HCI3) 22.10 ((CH3)2CH), 
41.90 (NHÇH2CO2PF), 42.75 (O2CNHÇH2CO), 66.93 (OCH(CH3)2), 70.05 
(C6H 5ÇH 2 ), 128.66, 128.73 & 129.00 (aromatic), 136.60 (quat. aromatic), 
157.15 (urethane CO), 170.00 (CH2CONH) and 176.80 (£ 0 2 CH(CH3)2); m/z 
(El) 309 ([M + H]+, 3.5%), 265 (5), 201 (12.0), 159 (18.0), 141 (9.6), 108 
(43.7), 91 (80.6), 79 (24.8), 65 (11.3), 56 (20.6) and 43 (100).
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Isopropyl glycyl glycinate (8 )
To a solution of isopropyl carboxybenzyl glycyl glycinate (7) (0.10 g, 0.33 
mmol) in isopropanol (50 cm^) was added 10% palladium on carbon (20 mg). 
The flask was sealed, flushed with argon then hydrogen and hydrogen was 
bubbled through the reaction mixture with vigorous stirring. The reaction was 
followed to completion by tic and worked up after 2 h. The reaction mixture 
was filtered through a pre-washed celite pad and the filtrate was concentrated 
under reduced pressure to give pure (8 ) as a white solid (40 mg, 71%), m.p. 
120 °C (decomp.); m/z (Found: [M + H]+, 175.1083. C7H 15N2O3 requires 
175.1083); Ôh (200 MHz; 2 H 2 O) 1.21 (6 H, d, CH(CH3 )2 ), 3.32 (2H, s, 
NH2ÇH 2CO), 3.95 (2H, s, NHCH2CO) and 5.00 (IH, sep, CH(CH3)2 ); ôc 
(50.3 MHz; 2 H 2 O) 23.66 (CH (CH 3 ) 2 ), 44.36 (NH2 C H 2 CO), 46.48 
(NHÇH2CO2), 73.67 (CH(CH3)2), 174.15 (amide CO) and 179.07 (ester CO); 
m/z (El) 174 (M+, 15.2%), 159 (4.2), 145 (12.7), 132 (14.1), 115 (21.0), 105 
(8.5), 87 (58.0), 75 (26.5), 58 (28.2) and 43 (100). Some ex-dimer formation 
m/z 349 in Cl = [2M + H]+.
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Isopropyl carboxybenzyI-(2S)-Ieucyl-(25)-aIanyI glycyl glycinate 
(9)
This compound was prepared in a manner identical to that for the dipeptide 
(3), using (4) (1.06 g, 3.2 mmol) and (8 ) (0.55 g, 3.2 mmol) (it was found 
that it was unnecessary to add an equivalent of NMM to the DMF solution of 
(8 ) since this is a free amine and not a hydrochloride salt). The dissolution of 
the amine (8 ) required gentle heat. The crude tetrapeptide was purified by 
crystallisation from methanol/ water to afford (9) as a white solid (1.02 g, 
63%), m.p. 125-6 °C; (Found: C, 58.75; H, 7.6; N, 11.45. Calc, for 
C24H36N4 O7 : C, 58.5; H, 7.4; N, 11.4%); m/z (Found; [M + H]+, 493.2649. 
Calc, for C24H37N4O7 : 493.2584); [a]“  -26.8 (c 0.5 in CH3 OH); §h (200
MHz; C2HCI3) 0.92 (6 H, d, CH2CH(CH3)2), 1.23 (6 H, d, OCH(CH3)2), 1.38 
(3H, d, CHCH3), 1.49-1.75 (3H, m, CH2CH(CH3)2), 3.97 (4M, d, NHCH2CO 
and NHCH2CO2), 4.16 (IH, q, CHCH3), 4.39 (IH, t, CHCH2), 5.01 (IH, sep, 
CH(CH3)2), 5.09 (2H, s, C6H5CH2), 5.28, 6.63, 6.85 & 7.08 (all IH, d, NH’s) 
and 7.34 (5H, s, aromatic); ôc (50.3 MHz; C^HCls) 18.68 (CHÇH3), 21.56 
(0CH(£H3)2), 21.92 (CH2CH(CH3)2), 22.82 & 24.56 (CH2CH(£H3)2), 41.43 
(£ .H 2 C H (C H 3 )2 ), 41.99 (NHÇH 2 CO), 42.82 (N H ÇH 2 C O 2 ), 48.85 
(N H CH (CH 2)C0), 53.45 (NHCH(CH3)C0), 66.82 (C6H 5C.H2 ), 69.16 
(0 CH (CH 3)2 ), 127.76, 127.98 & 128.35 (aromatic CH’s), 136.21 (quat. 
aromatic), 156.30 (urethane CO), 168.98, 169.13 & 172.52 (amide CO’s) and
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173.60 (ester CO); m/z (FAB) 515 ([M + Na]+, 100%), 493 ([M + H]+, 35), 
319 (5.4), 265 (5.2) and 147 (52.2).
Isopropyl carboxybenzyI-(2S)-Ieucyl-(2S)-alanyl-(2S)-aIanyI 
glycinate (1 0 )
This compound was prepared in a manner identical to that for the glycyl
analogue (9), using the (2S)-alanine dipeptide and follow (1), (7) and (8 ))
( 2 1 0  mg, 1 .1 0  mmol) to give an off-white solid which was recrystallised from
ethyl acetate/ light petrol to give the tetrapeptide (10) as a white solid (410
mg, 74%), m.p. 200-2 °C; (Found: C, 59.1; H, 7.55; N, 10.85. Calc, for 
C2 5 H3 8 N4 O7 : C, 59.25; H, 7.55; N, 11.05%); -54.2 (c 0.5 in CH3 OH);
5h (200 MHz; C2HCI3) 0.94 & 0.96 (6 H, d, CH2 CH(CH.3 )2 ), 1.22 (6 H, d, 
0 CH(CH3)2), 1.38 (6 H, d, ala CH3’s), 1.68 (3H, m, CH2CH(CH3)2), 3.95 (2H, 
m, NHCH2CO2), 4.30 (IH, q, NHCH(CH2)CO), 4.5 & 4.65 (IH  & IH, t & t, 
ala CHCH3 ’s), 5.05 (IH, sep, 0 CH(CH3)2), 5.10 (2H, s, C6H5CH2), 5.5 (IH, d,
u r e t h a n e  N H ) ,  6.95-7.15 (3H, m ,  a m i d e  N H ’ s )  a n d  7.35 (5H, s, a r o m a t i c  
C H ’ s ) ;  Ô C  (50.3 MHz; C2HCI3) 19.20 ( b o t h  a l a  CH3 ’s), 22.23 (OCH(CH3)2), 
22.51 (CH2 C H (C H 3 )2 ), 23.45 & 25.26 (CH2 C H (C H 3 ) 2 ), 42.05 
(C H 2 C H (C H 3 )2 ), 42.47 ( N H C . H 2 C O ) ,  49.20 ( N H £ . H ( C H 2 ) C O ) ,  49.58 
( N H C . H ( C H 3 ) C 0 ) ,  54.26 ( N H £ H ( C H 3 ) C 0 ) ,  67.54 (C6H 5Ç H 2 ), 69.72 
( 0 £ H ( C H 3 ) 2 ) ,  128.41, 128.71 & 129.04 ( a r o m a t i c  C H ’ s ) ,  136.68 ( q u a t .
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aromatic), 156.93 (urethane CO) and 169.73, 172.47, 173.06 & 173.09 
(amides and ester CD's).
Isopropyl carboxybenzyI-(2S)-leucyl-(2S)-alanyI-(2jR)-alanyl 
glycinate (1 1 )
This compound was prepared in a manner identical to that for the (2S) 
enantiomer (10), using the (2R) alanine dipeptide (700 mg, 3.71 mmol) to 
give an off-white solid which was recrystallised from methanol/ water to give 
the tetrapeptide (11) as a white solid (870 mg, 46%), m.p. 185-187 °C 
(Found: C, 59.25; H, 7.45; N, 10.70. Calc for C25H38N4O7 : C, 59.25; H, 7.55 
N, 11.05%); m/z (Found: [M + H]+, 507.2827. Calc, for C2 5 H 3 9 N 4 O 7 
507.2819); [a]p -12.7 (c 0.5 in CH3OH); Sh (200 MHz; C^HClg) 0.89 & 0.90
(6 H, m, CH2CH(CH3)2), 1.22 (6 H, d, OCH(CE3)2>, 1.40 (6 H, d, ala CH3 ’s), 
1.59 (3H, m, C Ii2 C E (C H 3 )2 ), 3.95 (2H, m, NHCH2 CO), 4.22 (IH . q, 
NHCH(CH2)C0 ),4 .4 -4 .7  (2H, m, both ala CH’s), 5.08 (IH, sep, OCH(CH3)2), 
5.11 (2H, s, C6H5CH2), 5.49 (IH, d, urethane NH), 7.05 (3H, m, amide NH’s) 
and 7.35 (5H, s, aromatic CH’s); 5c (50.3 MHz; C2HCI3) 18.33 & 18.50 (both 
ala CH3 ’s), 22.23 (OCH(C.H3 )2 ), 23.46 (CH2 C H (C H 3 ) 2 ), 25.19 
(C H 2 C H (C H 3 )2 ), 41.92 (C H 2C H (C H 3 )2 ). 41.99 (NH£,H2C0), 49.24 
(NH£H(CH2)C0), 49.49 (NHCH(CH3)CO), 54.32 (NHCH(CH3)CO), 67.77 
(C6H5CH2), 69.73 (0 £H(CH 3)2), 128.62, 128.76 & 129.04 (aromatic CH’s),
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136.45 (quat. aromatic), 157.00 (urethane CO) and 169.98, 172.95, 173.3 &
173.5 (amides and ester CO’s); m/z (Cl) 507 ([M + H]+, 34%), 489 (6.1), 399 
(91.9), 373 (6.3), 351 (32.1), 319 (13.8), 307 (8.9), 282 (33.8), 254 (6.1), 
189 (14.6), 176 (6.0), 147 (34.0), 108 (23.1) and 91 (100).
Isopropyl carboxybenzyI-(2S)-leucyl-(2S)-alanyl glycinate (12)
This compound was prepared in a manner identical to that for the tetrapeptide 
(9), using the monoprotected glycine derivative (6 ) (0.47 g, 2.99 mmol) to 
give the tripeptide as an off-white sohd. Purification by silica chromatography 
using dichloromethane/ methanol (95:5) as the eluant gave the pure peptide 
(12) as a white solid (0.72 g, 55%), m.p. 137 °C; (Found; C, 60.8; H, 7.7; N, 
9.6. Calc, for C22H 33N 3O6 : C, 60.7; H, 7.65; N, 9.65%); m/z (Found: M+, 
435.2377. Calc, for C2 2H33N3O6 : 435.2369); 5h (200 MHz; C2HCI3) 0.92 
(6 H, d, CH2 C H (C H 3 )2 ), 1.25 (6 H, d, OCH(CH.3 ) 2 ), 1.37 (3H, d, 
NHCH(CH3)C0 ), 1.60 (3H, m, CH2CH(CH3)2), 3.96 (2H, d, NHCH2CO2), 
4.20 (IH, q, NHCH(CH2)C0 ), 4.58 (IH, quin, NHCH(CH3)CO), 5.09 (IH, sep, 
0 CH(CH3)2), 5.10 (2H, s, C6H5CH2), 5.36 (IH, d, urethane NH), 6.72 & 6 .8 8  
(2H, d & t, amide CO’s) and 7.36 (5H, s, aromatic CH’s). Ôq (50.3 MHz; 
C2HCI3) 18.71 (CHCH3), 22.22 (0CH(CH3)2), 23.47 (CH2CH(CH3)2), 25.16 
(C H 2 C H (£.H 3 )2 ), 41.82 (CH 2 C H (C H 3 )2 ), 42.20 (NHÇH2 CO), 49.20 
(N H C H (CH 2)C0), 54.13 (NHCH(CH3)C0), 67.65 (C6 H 5Ç H 2 ), 69.83
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(0 £.H(CH 3)2 ), 128.57, 128.72 & 129.03 (aromatic CH’s), 136.58 (quat. 
aromatic), 148.74 (urethane CO), 169.62 (ester CO) and 172.64 & 172.72 
(amide CO’s); m/z (El) 435 (M+, 5.0%), 379 (15.5), 319 (10.5), 291 (23.0), 
248 (33.2), 220 (36.9), 184 (8.7), 176 (58.3), 134 (17.0), 107 (8.9), 99 (5.1) 
and 91 (100).
C arboxybenzyl-(2S)-leucyl-(2S)-alanyl glycine (13)
This compound was prepared in a manner identical to that for (4), using the 
tripeptide (12) (110 mg, 253 mmol) to give a white precipitate which was 
dissolved in 1 mol dm-3 NaOH (5 cm3, 5 mmol) and neutralised to pH 2 using 
1 moldm'3 HCl, the resultant white precipitate was filtered, washed with 1 mol 
dm-3 HCl and dried to give pure (13) as a white solid (83 mg, 83%), m.p. 
149 °C; (Found: C, 58.2; H, 6.75; N, 10.65. Calc, for C 19H27N3O6 : C, 58.0; 
H, 6.9; N, 10.7%); m/z (Found: [M + H]+, 394.1970. C 19H28N3O6 : 394.1978); 
6 h  (300 MHz; C2 H 3 O 2 H) 1.12 (6 H, m, CH2 C H (C H 3 )2 ), 1.57 (3H, d, 
NHCH(CH3)C0 ), 1.78 (2H, m, CH2CH(CH3)2), 1.90 (IH, m, CH2CH(CH3)2), 
4.1 (2H, m, NHCH2 CO), 4.33 (IH, t, NHCH(CH 2 )C0 ), 4.62 (IH , q, 
NHCH(CH3)C0 ), 5.29 (2H, s, C6H5CH2) and 7.58 (5H, m, aromatic CH’s); 5c 
(75.47 MHz; C2H 3O2H) 18.30 (CHÇH3), 22.11 (CH2£H (C H 3)2), 23.75 & 
26.15 (CH2CH(CH3)2 ), 42.03 (CH2CH(CH3)2), 42.20 (NHCH2CO), 50.39 
(NHCH(CH2)C0), 55.40 (NHCH(CH3)CO), 68.11 (C6H5ÇH2), 129.14, 129.31 
& 129.76 (aromatic CH’s), 138.43 (quat. aromatic), 159.04 (urethane CO) and
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173.04, 175.34 & 175.55 (amide and acid CO’s); m/z (Cl) 394 ([M + H]+, 
100%), 376 (59.1), 337 (10.8), 286 (10.1) and 260 (6.1).
M ethyl carboxybenzyl-(2S)-leucyI-(2S)-alanyI-(2S)-aIaninate (14)
This compound was prepared in a manner identical to that for the glycyl 
analogue (12), using the monoprotected (25')-alanine derivative (2) (660 mg,
4.73 mmol) to give the tripeptide as an off-white solid which was 
recrystallised from methanol/ water to give pure (14) as a white solid (1.36 g, 
6 8 %), m.p. 174-6 °C; (Found: C, 59.75; H, 7.5; N, 9.9. Calc for 
C21H31N3O6 : C, 59.85; H, 7.4; N, 9.95%); m/z (Found: [M + H]+, 422.2294. 
Calc, for C2 1H 32N 3O 6 : 422.2291); ôy (300 MHz; C2 HCI3 ) 0.91 (6 H, d, 
CH2CH(CH3)2), 1.38 (6 H, m, both ala CH3 ’s), 1.60 (3H, m, CH2CH(CH3)2), 
3.75 (3H, s, OCH3), 4.21 (IH, m, NHCH(CH2 )CO), 4.55 (2H, m, both ala 
CH’s), 5.12 (2H, s, C6H5CH2), 5.40 (IH, d, urethane NH), 6.78 (IH, d, amide 
NH), 6.89 (IH, d, amide NH) and 7.35 (5H, s, aromatic CH’s); ôc (75.47 
MHz; C2HCI3) 18.29 (both ala CH3 ’s), 22.07 (CH2£H(CH3)2), 23.82 & 24.86 
(CH2 CH(CH3)2 ), 41.79 (CH2CH(CH3)2 ), 48.28 (NHCH(CH2 )CO), 48.94 
(NHCH(CH3)C0 ), 52.63 (NHCH(CH3)C0 2 CH3 ), 53.76 (CO2CH3 ), 67.30 
(C 6H 5Ç H 2 ), 128.22, 128.40 & 128.72 (aromatic CH’s), 136.35 (quat. 
aromatic), 156.44 (urethane CO), 171.72 (ester CO) and 172.36 & 173.28 
(amide CO’s); m/z (Cl) 422 ([M + H]+, 100%) and 314 (6.0).
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Carboxybenzyl-(2S)-leucyl-(2S)-alanyl-(2S)-alanine (15)
This compound was prepared in a manner identical to that for the glycine 
analogue (13), using the tripeptide (14) (350 mg, 0.83 mmol) to give a white 
precipitate which was dissolved in 1 mol dm-3 NaOH (5 cm^, 5 mmol) and 
neutralised to pH 2 using 1 mol dm-3 HCl, the resultant white precipitate was 
filtered, washed with 1 mol dm-3 HCl and dried to give pure (15) as a white 
solid (290 mg, 85%), m.p. 183-4 °C; (Found: C, 57.5; H, 6.9; N, 9.95. Calc, 
for C20H29N3O6 .O.5 H2O: C, 57.7; H, 7.25; N,10.1%); m/z (Found; [M + H]+, 
408.2130. Calc, for C20H30N3O6 : 408.2135); Ôh (300 MHz; C2H3O2H) 1.14 
(6 H, m, CH2 C H (C E j) 2 ), 1.55 (6 H, m, hoth ala CH3 ’s), 1.73 (2H, t, 
N HCH(CK 2 CH(CH 3 )2 )CG), 1.89 (IH, m, CH2 CH (CH 3 )2 ), 4.32 (IH, t, 
N H C H (C H 2C H (C H 3 )2 )C0 ), 4.53 (2H, m, hoth ala CH’s), 5.28 (2H, s, 
C6H5CH2) and 7.52 (5H, m, aromatic CH’s); ôc (75.47 MHz; C2H3O2H) 17.65 
& 18.36 (both ala CH3 ’s), 22.14 (CH2 C_H(CH3 )2 ), 23.72 & 26.12 
(CH2CH(CH3)2), 42.29 (QH2CH(CH3)2), 49.70 (NHCH(CH3)C02H), 50.28 
(NHCH(CH2)C0), 55.19 (NHCH(CH3)CO), 67.99 (C6H5CH2), 129.05,129.28 
& 129.75 (aromatic CH’s), 138.44 (quat. aromatic), 158.83 (urethane CO) and
174.81 & 175.42 (amide CO’s); m/z (Cl) 408 ([M + H]+, 100%), 390 (5.8), 
336 (7.4), 300 (22.3), 274 (11.5), 224 (5.3), 185 (8 .8 ), 143 (6.2) and 90 
(11.7).
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Methyl carboxybenzyl-(2S)-leucyl-(2S)-alanyl-(2jR)-alanmate (16)
This compound was prepared in a manner identical to that for the (2S,2S,2S) 
epimer (14), using the monoprotected (2/?)-alanine derivative (210 mg, 1.51 
mmol) to give the tripeptide as an off-white solid which was recrystallised 
from methanol/ water to give pure (16) as a white solid (420 mg, 6 6 %), m.p. 
164 °C; m/z (Found: [M + H]+, 422.2299. Calc, for C21H32N3O6 : 422.2291); 
5h (200 MHz; C2HCI3) 0.92 (6 H, d, CH2CH(CH3)2), 1.39 (6 H, m, both ala 
C H s’s), 1.65 (3H, m, CH2 CH(CH 3 )2 ), 3.72 (3H, s, OCH3 ), 4.18 (IH, m, 
NHCH(CH2)C0 ), 4.53 (2H, m, both ala CH’s), 5.11 (2H, s, C6H5CH2), 5.23
(IH, d, urethane NH), 6.60 (IH, d, amide NH), 6.89 (IH, d, amide NH) and
7.36 (5H, s, aromatic CH’s). Sc (50.3 MHz; C2HCI3) 18.08 & 18.20 (both ala 
CH 3 's), 21.98 (CH2 £ H (C H 3)2 ), 23.13 & 24.95 (CH2 CH (CH 3 )2 ), 41.49 
(CH2CH(CH3)2), 48.28 (NHCH(CH2)CO), 52.60 (NHCH(CH3)C0), 54.13 
(NH£H(CH3)C0 2 CH3), 67.53 (C6H5CH2), 128.38, 128.51 & 128.77 (aromatic 
CH’s), 136.19 (quat. aromatic), 156.61 (urethane CO), 171.61 (ester CO) and 
172.25 & 173.40 (amide CO’s); m/z (Cl) 422 ([M + H]+, 100) and 314 (7.0).
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Carboxybenzyl-(25)-leucyl-(2S)-alanyl-(2/?)-alanine (17)
This compound was prepared in a manner identical to that for the (2S,2S,2S) 
epimer (15), using the tripeptide (16) (440 mg, 1.05 mmol) to give a white 
precipitate which was dissolved in 1 mol d m -5 NaOH (5 cm^, 5 mmol) and 
neutralised to pH 2 using 1 mol dm-^ HCl, the resultant white precipitate was 
filtered, washed with 1 mol dm-3 HCl and dried to give pure (17) as a white 
solid (230 mg, 54%), m.p. 170 °C; (Found: C, 58.9; H, 7.2; N, 10.2. Calc for 
C20H29N3O6 : C, 58.95; H, 7.15; N, 10.3%); m/z (Found: [M + H]+, 408.2136. 
Calc, for C20H30N3O6 : 408.2135); Ôh (300 MHz; C2H 3O2H) 1.14 (6 H, m, 
C H 2 C H (C H 3 )2 ), 1.57 & 1.62 (6 H, d, both ala CH3 ’s), 1.76 (2H, t, 
N HCH(CH 2CH (CH 3 )2 )C0 ), 1.93 (IH, m, CH2CH (CH 3 )2 ), 4.31 (IH, t, 
NH CH (CH 2CH (CH 3 )2 )CO), 4.62 (2H, m, both ala CH’s), 5.31 (2H, m, 
C6H5CH2) and 7.57 (5H, m, aromatic CH’s); ôc (75.47 MHz; C % 3 0 % ) 18.04 
& 18.23 (both ala CH3 ’s), 22.15 (CH2 C H (C H 3 ) 2 ), 23.71 & 26.19 
(CH2CH(£H 3)2), 42.15 (£H 2CH(CH3)2), 49.59 (NHCH(CH3)C02H), 50.38 
(NHCH(CH2)C0), 55.72 (NHÇH(CH3)C0), 68.22 (C6H5ÇH2), 129.24, 129.35 
& 129.78 (aromatic CH’s), 138.38 (quat. aromatic), 159.15 (urethane CO) and
174.60 & 175.64 (amide CO’s); m/z (Cl) 408 ([M + H ]+, 100%), 390 (6.0), 
300 (35.3), 274 (15.1) and 147 (8.4).
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Methyl carboxybenzyl-(2S)-Ieucyl-(2S)-aIanyl-(2S)-valinate (18)
This compound was prepared in a manner identical to the for the glycine 
analogue (12), using the monoprotected (25)-valine derivative (250 mg, 1.50 
mmol) to give the tripeptide as an off-white solid which was recrystallised 
from methanol/ water to give pure (18) as a white solid (500 mg, 67%), m.p. 
173 °C; (Found: C, 61.3; H, 7.9; N, 9.2. Calc for C23H35N3O6 : C, 61.45; H, 
7.85; N, 9.35%); m/z (Found: M+, 450.2612. Calc, for C2 3 H 3 5 N 3 O 6 : 
450.2604); Ôh (300 MHz; C2HCI3) 0.95 (12H, m, leu CH3 ’s & val CH3 ’s),
1.37 (3H, d, ala CH3 ), 1.60 (3H, m, CH.2 C H (C H 3 )2 ), 2.15 (IH , m, 
CHCH(CH3)2), 3.73 (3H, s, OCH3), 4.22 (IH, m, NHCH(CH3)C0 ), 4.51 (2H, 
m, leu & val CH’s), 5.10 (2H, s, C6H5CH2), 5.35 (IH, d, urethane NH), 6.72
(IH, d, amide NH), 6.81 (IH, d, amide NH) and 7.35 (5H, s, aromatic CH’s); 
ÔC (75.47 MHz; C2HCI3) 17.92 & 18.04 (CHCH(CH3)2 ), 19.07 (CHCH3), 
22.08 (CH2£H(CH3)2), 23.08 & 24.86 (CH2CH(CH3)2), 31.35 (CH£H(CH3)2),
41.81 (CH2CH(CH3)2 ), 49.13 (NH£H(CH2)C0), 52.35 (NHCH(CH3)C0), 
53.71 (NHCH(CH)CO), 57.47 (OCH3), 67.33 (C6H5ÇH2), 128.24, 128.41 &
128.73 (aromatic CH’s), 136.23 (quat. aromatic), 156.38 (urethane CO), 
172.04 (ester CO) and 172.30 & 172.44 (amide CO’s); m/z (Cl) 450 (M+, 
100%), 395 (6.2), 357 (20.5), 342 (27.4) and 147 (11.1).
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C arboxybenzyl-(2S)-leucyl-(2S)-alanyl glycyl glycine-/? 
nitroanilide (19)
This compound was prepared in a manner identical to that for the tetrapeptide 
(9) using the mixed anhydride to couple the tripeptide (13) (65 mg, 0.165 
mmol) to glycine-p-nitroaniline (32.2 mg, 0.165 mmol). The reaction was 
carried as described for the preparation of (9) with the exception that NMM 
(18 mm3, 0.165 mmol) was added to the solution of glycine-p-nitroaniline. 
The reaction was followed to completion using tic and compound (19) was 
obtained as a pale yellow solid (15 mg, 16%); Ôh (200 MHz; C % 3 0 % ) 0.95 
(6 H, m, CH2 C H (C H 3 )2 ), 1.45 (3H, m, CH 2 C H (C H 3 )2 ), 3.88 (2H, d, 
NHCH2C0 NHPhN0 2 ), 3.96 (2H, s, NHCH2CO), 4.18 (2H, m, NHCH(CH2) & 
NHCH(CH3)), 5.09 (2H, s, C6H5CH2), 7.35 (5H, m, C6H5CH2), 7.83 (2H, d, 
p-nitroanilide protons 2 & 6 ) and 8.22 (2H, d, p-nitroanilide protons 3 & 5).
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C arboxybenzyl-(2S)-leucyl-(2S)-alanyl-(2/î)-alanyl glycine-p- 
nitroanilide (2 0 )
This compound was prepared in a manner identical to that for the glycyl 
analogue (19) using the (2iR)-alanine tripeptide (17) (190 mg, 0.467 mmol) 
to give a pale yellow solid which was recrystallised from methanol/ water to 
give pure (20) as a pale yellow solid (115 mg, 42%), m.p. 188 °C (decomp); 
(Found: C, 57.0; H, 6.1; N, 14.05. Calc for C28H36N6 0 g: C, 57.55; H, 6.2; N, 
14.35%); ÔH (300 MHz; C^HgO^H) 0.70 (3H, d, CH2CH(CH3)2), 0.78 (3H, d, 
CH2CH(CH3)2), 1.43 (9H, m, CH2CH(CH3)2 ), (25)-CHCH3, (2Æ)-CHCH3), 
4.09 (2H, dd, NHCH2CONHPhN0 2 ), 4.11 (IH, m, NHCH(CH2)C0 ), 4.28 (2H, 
m, both ala CH’s), 5.06 (2H, s, C6H5CH2), 7.32 (5H, s, C6H5CH2), 8.03 (2H, 
d, p-nitroanilide protons 2 & 6 ) and 8.17 (2H, d, p-nitroanilide protons 3 & 
5); ÔC (74.47 MHz; C % 3 0 2 H) 17.11 (both ala CH3 ’s), 21.88 (CH2£H(CH3)2), 
23.65 & 25.96 (CH2CH(£H3)2), 42.17 (NHCH2CO), 51.36 (NHCH(CH2)CO), 
51.90 (NH£H(CH3)C0), 54.97 (NHCH(CH3)C0), 68.04 (C6H5CH2 ), 120.95 
(p-nitroanilide carbons 2 & 6 ), 126.00 (p-nitroanilide carbons 3 & 5), 129.11, 
129.32 & 129.76 (Cbz CH’s), 138.43 (Cbz quat. aromatic), 145.09 (p- 
nitroanilide quat. carbon 1), 146.01 (p-nitroanilide quat. carbon 4), 159.03 
(urethane CO), 170.64 (NHCH2£ 0 NHPhN0 2 ) and 176.07, 176.36 & 176.52
(amide CO’s).
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Peptide assay for recombinant adenovirus 2 L3 23 kDa proteinase
Substrate: 2 mg/ml LSGAGFSW in water
Assay buffer: 50 mM Tris, 10 mM EDTA, pH 8 , add 7.8 |ll mercaptoethanol 
per 50 ml immediately before use.*
Activating peptide: 10 p.g/ml pVI-CT (GVQSLKRRRCF) in water
Reaction mixture:
10 pi Proteinase 
10 pi activating peptide 
25 pi assay buffer 
Leave 5 min at room temperature 
10  pi substrate
Incubate at 37 °C for required time period.
For CE analysis the reaction was stopped by adding 10 pi of CE buffer (pH
2.5 phosphate) or 1% TEA to 10 pi of sample. 80 pi of water was added and 
the mixture was filtered before loading onto CE.
For HPLC analysis 100 pi 0.1% TFA was added to stop the reaction. The 
mixture was filtered and 25 pi was applied to a C18 reverse phase column. 
Buffer A: 0.1% TFA in water 
Buffer B: 0.1% TFA in acetonitrile 
Program: LSGAG 
Wavelength: 226 nm FSD 0.2
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*Not all proteinase preparations require mercaptoethanol - but the activity of 
most is increased by its incorporation in the assay.
The proteinase is not particularly stable and repeated freezing/ thawing results 
in a rapid deterioration of enzyme activity. The enzyme is best kept at -70 °C, 
and then thawed and kept on ice as required.
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APPENDIX ONE.
PROTEINASE ASSAY: 10 |il Proteinase
10 |Lil Activating Peptide 
25 \il Tris EDTA pH 7.8 
10 jil Substrate (AcLRGAGRSR)
[Assay]
-300 nM 
11.4 iiM 
21 mM/3.8 mM 
342 [iM
10 III Inhibitor in DMSO or MeOH Given below
RESULTS INITIAL RATE xlOOO
Assay 1 2 3 M e a n  s.e.m. % Inhibition Estimated Kj
CONTROL 35.06 34.58 36.29 3 5 .3 1 0.51
DMSO 0.31% 34.81 35.51 3 1 .6 5 3 4 .0 0 1.19
(9) 0.031 mM in DMSO 34.98 3 5 3 6 34.39 3 4 .9 1 0.28 0
DMSO 1.54% 31.35 2 9 7 0 42.13 3 4 .3 9 3 .9 0
(9) 0.006 mM in DMSO 33.76 37.41 31.45 3 4 .2 1 1.73 0
MeOH 7.7% 25.53 2 7 .0 5 27.96 2 6 .8 5 0.71
( 1 0 )  0.15 mM in MeOH 28.50 27.05 29.11 2 8 .2 2 0.61 0
( 1 1 )  0.15 mM in MeOH 26.58 29.63 2 8 .0 1 2 8 .0 7 0.88 0
MeOH 7.7% 27.44 28.50 28.91 2 8 .2 8 0.44
( 1 0 )  0.77 mM in MeOH 17.60 13.94 21.56 1 7 .7 0 2.20 37.41 2.1 mM
(11) 0.77 mM in MeOH 19.63 25.61 27.17 2 4 .1 4 2.30 14.64 5.3 mM
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Conclusions:
No inhibition or the proteinase was obtained with (9) at either concentration 
used.
No inhibition of the proteinase was obtained with (10) or (11) at 0.15 mM.
Some inhibition was observed with the higher concentration of (10) and (11) 
as tabulated. Due to solubility problems a higher concentration of (9) was not 
achieved.
EFFECT OF (9), (10) AND (11) ON ADENOVIRUS PROTEINASE
OIL C I I
C = Matched Control For Inhibitor I
